metformin has been researched along with Aging in 206 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The antidiabetic medication metformin has been proposed to be the first drug tested to target aging and extend healthspan in humans." | 9.51 | Antecedent Metabolic Health and Metformin (ANTHEM) Aging Study: Rationale and Study Design for a Randomized Controlled Trial. ( Bubak, MT; Davidyan, A; Elliehausen, CJ; Karaman, R; Konopka, AR; Kuhn, KG; Kumari, S; Miller, BF; Schoenberg, HM; Scofield, RH; VanWagoner, TM, 2022) |
| "In combination with a novel carbohydrate modified diet, metformin enhanced 12-month weight loss and improved body composition in ethnically diverse normoglycemic, hyperinsulinemic women with midlife weight gain." | 9.22 | METFORMIN-SUSTAINED WEIGHT LOSS AND REDUCED ANDROID FAT TISSUE AT 12 MONTHS IN EMPOWIR (ENHANCE THE METABOLIC PROFILE OF WOMEN WITH INSULIN RESISTANCE): A DOUBLE BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF NORMOGLYCEMIC WOMEN WITH MIDLIFE WEIGHT GAIN. ( Freeman, R; Mogul, H; Nguyen, K, 2016) |
| "To evaluate the effect of testosterone replacement therapy (TRT) on body composition, insulin sensitivity, oxidative metabolism and glycaemic control in aging men with lowered bioavailable testosterone (BioT) levels and type 2 diabetes mellitus (T2D) controlled on metformin monotherapy." | 9.22 | Effect of testosterone on insulin sensitivity, oxidative metabolism and body composition in aging men with type 2 diabetes on metformin monotherapy. ( Andersen, M; Glintborg, D; Hermann, P; Hougaard, DM; Højlund, K; Magnussen, LV, 2016) |
| "In individuals with prediabetes, metformin ameliorated effector pathways that have been shown to regulate longevity in animal models." | 9.20 | Metformin improves putative longevity effectors in peripheral mononuclear cells from subjects with prediabetes. A randomized controlled trial. ( Avogaro, A; Bacalini, MG; Borelli, V; Cattelan, A; Ceolotto, G; de Kreutzenberg, SV; Fadini, GP; Franceschi, C; Garagnani, P; Mazzucato, M; Pagnin, E, 2015) |
| " Metformin, which is widely prescribed for type 2 diabetes mellitus (T2DM) patients, regulates blood sugar by inhibiting hepatic gluconeogenesis and promoting insulin sensitivity to facilitate glucose uptake by cells." | 9.12 | New Insight into the Effects of Metformin on Diabetic Retinopathy, Aging and Cancer: Nonapoptotic Cell Death, Immunosuppression, and Effects beyond the AMPK Pathway. ( Cheng, KC; Chiu, CC; Hsu, SK; Lin, YH; Mgbeahuruike, MO; Sheu, SJ; Wang, HD; Wu, CY; Yen, CH, 2021) |
| "Metformin is sometimes proposed to be an "anti-aging" drug, based on preclinical experiments with lower-order organisms and numerous retrospective data on beneficial health outcomes for type 2 diabetics." | 9.01 | Metformin and Aging: A Review. ( Glossmann, HH; Lutz, OMD, 2019) |
| " Antidiabetic biguanides such as metformin, which reduce hyperglycemia and hyperinsulinemia by decreasing insulin resistance, extend lifespan, and inhibit carcinogenesis in rodents." | 8.89 | Metformin: do we finally have an anti-aging drug? ( Anisimov, VN, 2013) |
| "Metformin, an oral anti-diabetic drug, is being considered increasingly for treatment and prevention of cancer, obesity as well as for the extension of healthy lifespan." | 8.88 | Metformin in obesity, cancer and aging: addressing controversies. ( Berstein, LM, 2012) |
| "This study aimed to characterize aging-induced tendinopathy in mouse Achilles tendon and also to assess the treatment effects of metformin (Met) on aging tendon." | 8.31 | Metformin improves tendon degeneration by blocking translocation of HMGB1 and suppressing tendon inflammation and senescence in aging mice. ( Brown, R; Hogan, MV; Onishi, K; Wang, JH; Zhang, J, 2023) |
| "Metformin, a commonly prescribed anti-diabetic medication, has repeatedly been shown to hinder aging in pre-clinical models and to be associated with lower mortality for humans." | 8.31 | Metformin use history and genome-wide DNA methylation profile: potential molecular mechanism for aging and longevity. ( Anderson, ZM; Chang, G; Cho, HR; Crutchley, KJ; Iwata, M; Marra, PS; Modukuri, M; Shinozaki, G; Tran, T; Wahba, NE; Yamanashi, T, 2023) |
| "d-galactose (DG)-induced rodent aging model has widely been used for the study of age-related dysfunctions of various organs, including gonads and uterus." | 8.12 | Effects of metformin on the uterus of d-galactose-induced aging mice: Histomorphometric, immunohistochemical localization (B-cell lymphoma 2, Bcl2-associated X protein, and active capase3), and oxidative stress study. ( Anima, B; Gurusubramanian, G; Jeremy, M; Kharwar, RK; Pankaj, PP; Rempuia, V; Roy, VK, 2022) |
| " We evaluated the therapeutic effects of metformin in D-galactose-induced aging." | 8.12 | Metformin alleviates neurocognitive impairment in aging via activation of AMPK/BDNF/PI3K pathway. ( Abo-Elsoud, RAA; Ameen, O; Samaka, RM, 2022) |
| "Our results suggest that metformin can be regarded as an anti-aging compound in Drosophila muscle." | 8.12 | Metformin suppresses progression of muscle aging via activation of the AMP kinase-mediated pathways in Drosophila adults. ( Inoue, YH; Kohno, N; Le, TD; Nishida, H; Ozaki, M; Suzuta, S, 2022) |
| "Metformin has been extensively used for the treatment of type 2 diabetes, and it may also promote healthy aging." | 8.12 | The Gut Microbiome, Metformin, and Aging. ( Induri, SNR; Kansara, P; Li, X; Saxena, D; Thomas, SC; Xu, F, 2022) |
| "To explore the novel linkage between a Western diet combining high saturated fat, sugar, and salt (HFSS) and neurological dysfunctions during aging as well as Metformin intervention, we assessed cerebral cortex abnormalities associated with sensory and motor dysfunctions and cellular and molecular insights in brains using HFSS-fed mice during aging." | 8.02 | A high fat, sugar, and salt Western diet induces motor-muscular and sensory dysfunctions and neurodegeneration in mice during aging: Ameliorative action of metformin. ( Bazan, NG; Duong, QA; Hong, S; Lu, Y; Nagayach, A; Peng, H; Pham, NB; Vuong, CA, 2021) |
| "Metformin and weight loss relationships with epigenetic age measures-biological aging biomarkers-remain understudied." | 8.02 | An epigenetic aging analysis of randomized metformin and weight loss interventions in overweight postmenopausal breast cancer survivors. ( Bonanni, B; Cardenas, A; Chung, FF; Cuenin, C; Hartman, SJ; Herceg, Z; Hubbard, AE; Johansson, H; Novoloaca, A; Nwanaji-Enwerem, JC; Sears, DD; Smith, MT; Van der Laan, L, 2021) |
| "Aging model was induced by d-galactose (DG), and the anti-aging effect of EA alone or in the presence of PPAR-γ antagonist GW9662, and in combination with metformin were evaluated." | 7.91 | Ellagic acid dose and time-dependently abrogates d-galactose-induced animal model of aging: Investigating the role of PPAR-γ. ( Askari, VR; Baradaran Rahimi, V; Mousavi, SH, 2019) |
| "1-1 μM) provides greater antiaging properties than both its high concentration (10 μM) and metformin (2." | 7.88 | Ellagic acid reveals promising anti-aging effects against d-galactose-induced aging on human neuroblastoma cell line, SH-SY5Y: A mechanistic study. ( Askari, VR; Mousavi, SH; Rahimi, VB, 2018) |
| " In the present study, we investigated the potential therapeutic effects of metformin (Met) and saxagliptin (Saxa), as insulin sensitizing agents, in a rat model of brain aging and AD using D-galactose (D-gal, 150 mg/kg/day, s." | 7.85 | Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin. ( Attia, A; El-Shenawy, S; Gomaa, N; Hassan, A; Hegazy, R; Kenawy, S; Zaki, H, 2017) |
| " We hypothesized that neonatal treatment with antidiabetic drug biguanide metformin would positively modify regulation of growth hormone--IGF-1--insulin signaling pathway slowing down aging and improving cancer preventive patterns in rodents." | 7.81 | Sex differences in aging, life span and spontaneous tumorigenesis in 129/Sv mice neonatally exposed to metformin. ( Anisimov, VN; Egormin, PA; Khaitsev, NV; Panchenko, AV; Popovich, IG; Semenchenko, AV; Trashkov, AP; Tyndyk, ML; Vasiliev, AG; Yurova, MN; Zabezhinski, MA, 2015) |
| " The chronic treatment of inbred 129/Sv mice with metformin (100 mg/kg in drinking water) slightly modified the food consumption but failed to influence the dynamics of body weight, decreased by 13." | 7.76 | Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice. ( Anisimov, VN; Berstein, LM; Egormin, PA; Kovalenko, IG; Piskunova, TS; Popovich, IG; Poroshina, TE; Rosenfeld, SV; Semenchenko, AV; Tyndyk, ML; Yurova, MV; Zabezhinski, MA, 2010) |
| " Here we show the chronic treatment of female outbred SHR mice with metformin (100 mg/kg in drinking water) slightly modified the food consumption but decreased the body weight after the age of 20 months, slowed down the age-related switch-off of estrous function, increased mean life span by 37." | 7.74 | Metformin slows down aging and extends life span of female SHR mice. ( Anisimov, VN; Berstein, LM; Egormin, PA; Kovalenko, IG; Piskunova, TS; Popovich, IG; Poroshina, TE; Semenchenko, AV; Tyndyk, ML; Yurova, MV; Zabezhinski, MA, 2008) |
| "To determine whether improvement of insulin resistance decreases blood pressure as well as obesity, metformin (100 mg/kg/d) or vehicle was administered for 20 weeks to 12-week-old male Otsuka Long-Evans Tokushima Fatty (OLETF) rats (n = 10 each), a newly developed animal model of non-insulin-dependent diabetes mellitus (NIDDM) with mild obesity, hyperinsulinemia, and hypertriglyceridemia." | 7.69 | Metformin decreases blood pressure and obesity in OLETF rats via improvement of insulin resistance. ( Inukai, K; Ishii, J; Kashiwabara, H; Katayama, S; Kikuchi, C; Kosegawa, I; Negishi, K; Oka, Y, 1996) |
| "Aging is a natural process, which plays a critical role in the pathogenesis of a variety of diseases, i." | 6.82 | Metformin in aging and aging-related diseases: clinical applications and relevant mechanisms. ( Chen, M; Chen, S; Gan, D; Lin, S; Shao, Z; Xiao, G; Zhong, Y; Zou, X, 2022) |
| "Metformin is a first-line therapy for type 2 diabetes." | 6.61 | Metformin: Mechanisms in Human Obesity and Weight Loss. ( Soukas, AA; Yerevanian, A, 2019) |
| "Metformin, which has demonstrated protective effects against several age-related diseases in humans, will be tested in the TAME (Targeting Aging with Metformin) trial, as the initial step in the development of increasingly effective next-generation drugs." | 6.53 | Metformin as a Tool to Target Aging. ( Barzilai, N; Crandall, JP; Espeland, MA; Kritchevsky, SB, 2016) |
| "Furthermore metformin seems to decrease cancer risk in diabetic patients." | 6.46 | Metformin for aging and cancer prevention. ( Anisimov, VN, 2010) |
| "Metformin, a clinical agent of type 2 diabetes, is reported as a potential geroprotector." | 5.72 | Metformin Protects Against Inflammation, Oxidative Stress to Delay Poly I:C-Induced Aging-Like Phenomena in the Gut of an Annual Fish. ( Hou, Y; Li, G; Li, S; Liu, K; Qiao, M; Sun, X; Zhu, H, 2022) |
| "Metformin is a widely used drug for treating type 2 diabetes and is also used for delaying sexual maturation in girls with precocious puberty." | 5.72 | Metformin treatment of juvenile mice alters aging-related developmental and metabolic phenotypes. ( Bartke, A; Fang, Y; Medina, D; Yuan, R; Zhu, Y, 2022) |
| "In addition, the benefits of metformin treatment of depression have been documented in a range of rodent studies and human trials, but few studies have probed into the effect of metformin on and the related mechanism in depressed elderly mice, especially in those APOE4 carriers." | 5.72 | Metformin alleviates the depression-like behaviors of elderly apoE4 mice via improving glucose metabolism and mitochondrial biogenesis. ( Chen, X; Dai, X; Lin, Y; Zhang, J, 2022) |
| "Aging is associated with central fat redistribution and insulin resistance." | 5.62 | Metformin alleviates stress-induced cellular senescence of aging human adipose stromal cells and the ensuing adipocyte dysfunction. ( Atlan, M; Auclair, M; Bereziat, V; Capeau, J; Fève, B; Foresti, R; Gorwood, J; Laforge, M; Lagathu, C; Le Pelletier, L; Mantecon, M; Motterlini, R, 2021) |
| "Carfilzomib is a first-line proteasome inhibitor indicated for relapsed/refractory multiple myeloma (MM), with its clinical use being hampered by cardiotoxic phenomena." | 5.62 | Elucidating Carfilzomib's Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin. ( Andreadou, I; Chatzistefanou, M; Davos, CH; Dimopoulos, MA; Efentakis, P; Gavriatopoulou, M; Nikolaou, PE; Papanagnou, ED; Psarakou, G; Terpos, E; Trougakos, IP; Varela, A, 2021) |
| "Low-grade inflammation is often higher in older adults and remains a key risk factor of aging-related morbidities and mortalities." | 5.56 | Metformin Reduces Aging-Related Leaky Gut and Improves Cognitive Function by Beneficially Modulating Gut Microbiome/Goblet Cell/Mucin Axis. ( Ahmadi, S; Ding, J; Jain, S; Justice, J; Kitzman, D; Kritchevsky, SB; McClain, DA; Mishra, SP; Nagpal, R; Razazan, A; Wang, B; Wang, S; Yadav, H, 2020) |
| "Metformin treatment caused astrocytes to alter reactive genes in a PD animal model." | 5.56 | Metformin regulates astrocyte reactivity in Parkinson's disease and normal aging. ( Choi, JH; Choi, YK; Go, J; Kim, KS; Lee, CH; Lee, TG; Park, HY; Rhee, M; Ryu, YK; Seo, YJ, 2020) |
| "The antidiabetic medication metformin has been proposed to be the first drug tested to target aging and extend healthspan in humans." | 5.51 | Antecedent Metabolic Health and Metformin (ANTHEM) Aging Study: Rationale and Study Design for a Randomized Controlled Trial. ( Bubak, MT; Davidyan, A; Elliehausen, CJ; Karaman, R; Konopka, AR; Kuhn, KG; Kumari, S; Miller, BF; Schoenberg, HM; Scofield, RH; VanWagoner, TM, 2022) |
| " In genetically heterogeneous HET3 mice, we found that chronic administration of encapsulated rapamycin by diet caused a measurable defect in glucose metabolism in both male and female mice as early as 1 month after treatment." | 5.48 | Metformin reduces glucose intolerance caused by rapamycin treatment in genetically heterogeneous female mice. ( Fernandez, E; Liu, Y; Salmon, AB; Strong, R; Weiss, R, 2018) |
| "Metformin has also recently been shown to beneficially alter gene splicing in normal humans." | 5.48 | Cellular stress and AMPK activation as a common mechanism of action linking the effects of metformin and diverse compounds that alleviate accelerated aging defects in Hutchinson-Gilford progeria syndrome. ( Finley, J, 2018) |
| "Treatment with metformin improved cardiovascular function and survival in mature animals of both genders." | 5.46 | Metformin ameliorates gender-and age-dependent hemodynamic instability and myocardial injury in murine hemorrhagic shock. ( Hake, PW; James, J; Lahni, P; Matsiukevich, D; O'Connor, M; Piraino, G; Wolfe, V; Zingarelli, B, 2017) |
| "Metformin treatment resulted in an increase in FRAP, GSH, SH, and PMRS activities in both age groups compared to respective controls." | 5.46 | Metformin Alleviates Altered Erythrocyte Redox Status During Aging in Rats. ( Garg, G; Rizvi, SI; Singh, AK; Singh, S, 2017) |
| "Metformin, a biguanide, is a widely used antidiabetic drug, which inhibits gluconeogenesis and is used to treat hyperglycemia in type 2 diabetes." | 5.46 | Antiaging Effect of Metformin on Brain in Naturally Aged and Accelerated Senescence Model of Rat. ( Garg, G; Rizvi, SI; Singh, AK; Singh, S, 2017) |
| " This is the first known metformin repurposing trial in non-diseased individuals, aimed specifically at the resistance exercise "non-responder" phenotype present in the aging population." | 5.24 | Metformin to Augment Strength Training Effective Response in Seniors (MASTERS): study protocol for a randomized controlled trial. ( Bamman, MM; Bush, HM; Kern, PA; Long, DE; Martz, JL; McGwin, G; Peck, BD; Peterson, CA; Tuggle, SC, 2017) |
| "The strong evidence of metformin use in subjects affected by type 2 diabetes (T2DM) on health outcomes, together with data from pre-clinical studies, has led the gerontological research to study the therapeutic potential of such a drug as a slow-aging strategy." | 5.22 | A blast from the past: To tame time with metformin. ( Boccardi, V; Mecocci, P; Xenos, D, 2022) |
| "In combination with a novel carbohydrate modified diet, metformin enhanced 12-month weight loss and improved body composition in ethnically diverse normoglycemic, hyperinsulinemic women with midlife weight gain." | 5.22 | METFORMIN-SUSTAINED WEIGHT LOSS AND REDUCED ANDROID FAT TISSUE AT 12 MONTHS IN EMPOWIR (ENHANCE THE METABOLIC PROFILE OF WOMEN WITH INSULIN RESISTANCE): A DOUBLE BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF NORMOGLYCEMIC WOMEN WITH MIDLIFE WEIGHT GAIN. ( Freeman, R; Mogul, H; Nguyen, K, 2016) |
| "To evaluate the effect of testosterone replacement therapy (TRT) on body composition, insulin sensitivity, oxidative metabolism and glycaemic control in aging men with lowered bioavailable testosterone (BioT) levels and type 2 diabetes mellitus (T2D) controlled on metformin monotherapy." | 5.22 | Effect of testosterone on insulin sensitivity, oxidative metabolism and body composition in aging men with type 2 diabetes on metformin monotherapy. ( Andersen, M; Glintborg, D; Hermann, P; Hougaard, DM; Højlund, K; Magnussen, LV, 2016) |
| "In individuals with prediabetes, metformin ameliorated effector pathways that have been shown to regulate longevity in animal models." | 5.20 | Metformin improves putative longevity effectors in peripheral mononuclear cells from subjects with prediabetes. A randomized controlled trial. ( Avogaro, A; Bacalini, MG; Borelli, V; Cattelan, A; Ceolotto, G; de Kreutzenberg, SV; Fadini, GP; Franceschi, C; Garagnani, P; Mazzucato, M; Pagnin, E, 2015) |
| " Metformin, which is widely prescribed for type 2 diabetes mellitus (T2DM) patients, regulates blood sugar by inhibiting hepatic gluconeogenesis and promoting insulin sensitivity to facilitate glucose uptake by cells." | 5.12 | New Insight into the Effects of Metformin on Diabetic Retinopathy, Aging and Cancer: Nonapoptotic Cell Death, Immunosuppression, and Effects beyond the AMPK Pathway. ( Cheng, KC; Chiu, CC; Hsu, SK; Lin, YH; Mgbeahuruike, MO; Sheu, SJ; Wang, HD; Wu, CY; Yen, CH, 2021) |
| "Apart from being a safe, effective and globally affordable glucose-lowering agent for the treatment of diabetes, metformin has earned much credit in recent years as a potential anti-aging formula." | 5.01 | Metformin as a geroprotector: experimental and clinical evidence. ( Lushchak, O; Piskovatska, V; Stefanyshyn, N; Storey, KB; Vaiserman, AM, 2019) |
| "The anti-hyperglycemic medication metformin has potential to be the first drug tested to slow aging in humans." | 5.01 | Taming expectations of metformin as a treatment to extend healthspan. ( Konopka, AR; Miller, BF, 2019) |
| "Recent advances indicate that biological aging is a potentially modifiable driver of late-life function and chronic disease and have led to the development of geroscience-guided therapeutic trials such as TAME (Targeting Aging with MEtformin)." | 4.98 | A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup. ( Aroda, VR; Bahnson, JL; Barzilai, N; Divers, J; Espeland, MA; Ferrucci, L; Justice, JN; Kritchevsky, SB; Kuchel, GA; Marcovina, S; Newman, AB; Pollak, MN, 2018) |
| " Antidiabetic biguanides such as metformin, which reduce hyperglycemia and hyperinsulinemia by decreasing insulin resistance, extend lifespan, and inhibit carcinogenesis in rodents." | 4.89 | Metformin: do we finally have an anti-aging drug? ( Anisimov, VN, 2013) |
| "Metformin, an oral anti-diabetic drug, is being considered increasingly for treatment and prevention of cancer, obesity as well as for the extension of healthy lifespan." | 4.88 | Metformin in obesity, cancer and aging: addressing controversies. ( Berstein, LM, 2012) |
| " I also discuss other potential anti-aging agents (calorie restriction, metformin, resveratrol and sirtuins) and their targets, interference with the TOR pathway and combination with antioxidants." | 4.84 | An anti-aging drug today: from senescence-promoting genes to anti-aging pill. ( Blagosklonny, MV, 2007) |
| "This study aimed to characterize aging-induced tendinopathy in mouse Achilles tendon and also to assess the treatment effects of metformin (Met) on aging tendon." | 4.31 | Metformin improves tendon degeneration by blocking translocation of HMGB1 and suppressing tendon inflammation and senescence in aging mice. ( Brown, R; Hogan, MV; Onishi, K; Wang, JH; Zhang, J, 2023) |
| " Furthermore, a low dose of metformin mitigated TSPC senescence and restored senescence-related functions, including proliferation, colony-forming ability, migration ability and tenogenic differentiation ability at the early stage of aging." | 4.31 | The Regulation of the AMPK/mTOR Axis Mitigates Tendon Stem/Progenitor Cell Senescence and Delays Tendon Aging. ( Cao, M; Dai, G; Li, Y; Lu, P; Rui, Y; Shen, R; Shi, L; Wang, H; Zhang, M; Zhang, Y, 2023) |
| " In this study, we explored the therapeutic effect of metformin on thymus degeneration in the accelerated aging mice, which was established by intraperitoneal injection D-galactose (120 mg/kg/day) for eight weeks." | 4.12 | Metformin ameliorates thymus degeneration of mice by regulating mitochondrial function. ( Chai, YR; Su, Q; Sun, Y; Yang, SP; Zhang, YR, 2022) |
| " We evaluated the therapeutic effects of metformin in D-galactose-induced aging." | 4.12 | Metformin alleviates neurocognitive impairment in aging via activation of AMPK/BDNF/PI3K pathway. ( Abo-Elsoud, RAA; Ameen, O; Samaka, RM, 2022) |
| "Our results suggest that metformin can be regarded as an anti-aging compound in Drosophila muscle." | 4.12 | Metformin suppresses progression of muscle aging via activation of the AMP kinase-mediated pathways in Drosophila adults. ( Inoue, YH; Kohno, N; Le, TD; Nishida, H; Ozaki, M; Suzuta, S, 2022) |
| "Metformin has been extensively used for the treatment of type 2 diabetes, and it may also promote healthy aging." | 4.12 | The Gut Microbiome, Metformin, and Aging. ( Induri, SNR; Kansara, P; Li, X; Saxena, D; Thomas, SC; Xu, F, 2022) |
| "To explore the novel linkage between a Western diet combining high saturated fat, sugar, and salt (HFSS) and neurological dysfunctions during aging as well as Metformin intervention, we assessed cerebral cortex abnormalities associated with sensory and motor dysfunctions and cellular and molecular insights in brains using HFSS-fed mice during aging." | 4.02 | A high fat, sugar, and salt Western diet induces motor-muscular and sensory dysfunctions and neurodegeneration in mice during aging: Ameliorative action of metformin. ( Bazan, NG; Duong, QA; Hong, S; Lu, Y; Nagayach, A; Peng, H; Pham, NB; Vuong, CA, 2021) |
| "Metformin, a commonly used well-tolerated treatment for type 2 diabetes, is being deployed in clinical trials to ameliorate aging in older nondiabetic humans." | 4.02 | Metformin Treatment in Old Rats and Effects on Mitochondrial Integrity. ( Aiken, JM; Goldwater, DS; Herbst, A; Hoang, A; Kim, C; McKenzie, D; Wanagat, J, 2021) |
| "Metformin and weight loss relationships with epigenetic age measures-biological aging biomarkers-remain understudied." | 4.02 | An epigenetic aging analysis of randomized metformin and weight loss interventions in overweight postmenopausal breast cancer survivors. ( Bonanni, B; Cardenas, A; Chung, FF; Cuenin, C; Hartman, SJ; Herceg, Z; Hubbard, AE; Johansson, H; Novoloaca, A; Nwanaji-Enwerem, JC; Sears, DD; Smith, MT; Van der Laan, L, 2021) |
| "To investigate the effects of metformin (Met) on middle-aged male mice aging induced by D-galactose." | 3.91 | [Interventional effects of metformin on senescence induced by D-galactose in middle-aged male mice]. ( Chen, C; Cheng, J; Gao, LY; Huang, XW; Jiang, HX; Liu, P; Liu, YL; Lu, MM; Zhang, Y, 2019) |
| "Aging model was induced by d-galactose (DG), and the anti-aging effect of EA alone or in the presence of PPAR-γ antagonist GW9662, and in combination with metformin were evaluated." | 3.91 | Ellagic acid dose and time-dependently abrogates d-galactose-induced animal model of aging: Investigating the role of PPAR-γ. ( Askari, VR; Baradaran Rahimi, V; Mousavi, SH, 2019) |
| " This study was designed to investigate the possible effect of Met on the d-galactose (d-gal)-induced aging in ovariectomized mice." | 3.88 | Metformin ameliorates the age-related changes of d-galactose administration in ovariectomized mice. ( Allahtavakoli, M; Fatemi, I; Hakimizadeh, E; Heydari, S; Kaeidi, A; Khaluoi, A; Shamsizadeh, A, 2018) |
| " We were able to show in vivo that reducing phospho-STAT3-miR-21 levels in C57/BL6 mice liver, by long-term treatment with metformin, protected mice from aging-dependent hepatic vesicular steatosis." | 3.88 | Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model. ( Belloni, L; Blandino, G; Di Cocco, S; Guerrieri, F; Levrero, M; Marra, F; Mori, F; Nunn, ADG; Pallocca, M; Pediconi, N; Piconese, S; Pulito, C; Sacconi, A; Salerno, D; Strano, S; Testoni, B; Vivoli, E, 2018) |
| "1-1 μM) provides greater antiaging properties than both its high concentration (10 μM) and metformin (2." | 3.88 | Ellagic acid reveals promising anti-aging effects against d-galactose-induced aging on human neuroblastoma cell line, SH-SY5Y: A mechanistic study. ( Askari, VR; Mousavi, SH; Rahimi, VB, 2018) |
| " Herein, we have investigated the beneficial effect of cotreatment with CRM-candidate drugs, rapamycin (an immunosuppressant drug and inhibitor of mammalian target of rapamycin) and metformin (an antidiabetic biguanide and activator of adenosine monophosphate kinase), against aging-induced oxidative stress in erythrocytes and plasma of aging rats." | 3.85 | Synergistic Effect of Rapamycin and Metformin Against Age-Dependent Oxidative Stress in Rat Erythrocytes. ( Garg, G; Rizvi, SI; Singh, AK; Singh, S, 2017) |
| " In the present study, we investigated the potential therapeutic effects of metformin (Met) and saxagliptin (Saxa), as insulin sensitizing agents, in a rat model of brain aging and AD using D-galactose (D-gal, 150 mg/kg/day, s." | 3.85 | Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin. ( Attia, A; El-Shenawy, S; Gomaa, N; Hassan, A; Hegazy, R; Kenawy, S; Zaki, H, 2017) |
| " Here, we analyzed indicators of EMT during kidney aging and investigated the protective effects and mechanisms of short-term regimens of caloric restriction (CR) or caloric restriction mimetics (CRMs), including resveratrol and metformin." | 3.85 | Alleviation of senescence and epithelial-mesenchymal transition in aging kidney by short-term caloric restriction and caloric restriction mimetics via modulation of AMPK/mTOR signaling. ( Cai, GY; Chen, XM; Cui, SY; Dong, D; Fu, B; Guo, YN; Hong, Q; Lv, Y; Ning, YC; Wang, JC, 2017) |
| "To identify distinct temporal likelihoods of age-related comorbidity (ARC) diagnoses: cardiovascular diseases (CVD), cancer, depression, dementia, and frailty-related diseases (FRD) in older men with type 2 diabetes (T2D) but ARC naïve initially, and assess the heterogeneous effects of metformin on ARCs and mortality." | 3.85 | Differential effects of metformin on age related comorbidities in older men with type 2 diabetes. ( Espinoza, SE; Habib, SL; Jo, B; Lorenzo, C; Wang, CP, 2017) |
| " We hypothesized that neonatal treatment with antidiabetic drug biguanide metformin would positively modify regulation of growth hormone--IGF-1--insulin signaling pathway slowing down aging and improving cancer preventive patterns in rodents." | 3.81 | Sex differences in aging, life span and spontaneous tumorigenesis in 129/Sv mice neonatally exposed to metformin. ( Anisimov, VN; Egormin, PA; Khaitsev, NV; Panchenko, AV; Popovich, IG; Semenchenko, AV; Trashkov, AP; Tyndyk, ML; Vasiliev, AG; Yurova, MN; Zabezhinski, MA, 2015) |
| "Clinical and experimental investigations demonstrated that metformin, a widely used anti-diabetic drug, exhibits cardioprotective properties against myocardial infarction." | 3.79 | Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon. ( Hall, AR; Hausenloy, DJ; McLaughlin, CP; Mocanu, MM; Whittington, HJ; Yellon, DM, 2013) |
| " The chronic treatment of inbred 129/Sv mice with metformin (100 mg/kg in drinking water) slightly modified the food consumption but failed to influence the dynamics of body weight, decreased by 13." | 3.76 | Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice. ( Anisimov, VN; Berstein, LM; Egormin, PA; Kovalenko, IG; Piskunova, TS; Popovich, IG; Poroshina, TE; Rosenfeld, SV; Semenchenko, AV; Tyndyk, ML; Yurova, MV; Zabezhinski, MA, 2010) |
| "In this issue of Cell Cycle, a new paper shows that metformin, an oral antidiabetic drug that activates AMP-activated protein kinase, prolongs both mean and maximal life span and prevents reproductive aging of female mice." | 3.74 | Cancer and aging: more puzzles, more promises? ( Blagosklonny, MV; Campisi, J, 2008) |
| " Here we show the chronic treatment of female outbred SHR mice with metformin (100 mg/kg in drinking water) slightly modified the food consumption but decreased the body weight after the age of 20 months, slowed down the age-related switch-off of estrous function, increased mean life span by 37." | 3.74 | Metformin slows down aging and extends life span of female SHR mice. ( Anisimov, VN; Berstein, LM; Egormin, PA; Kovalenko, IG; Piskunova, TS; Popovich, IG; Poroshina, TE; Semenchenko, AV; Tyndyk, ML; Yurova, MV; Zabezhinski, MA, 2008) |
| " This is largely due to the historical experience of lactic acidosis with phenformin, despite the fact that metformin does not predispose to this when compared with other therapies." | 3.73 | Contraindications can damage your health--is metformin a case in point? ( Holstein, A; Stumvoll, M, 2005) |
| "To determine the relationship between hyperinsulinemia and hypertension in spontaneously hypertensive rats (SHR), the antihyperglycemic agent metformin was administered to SHR and their Wistar-Kyoto (WKY) controls, and its effects on plasma insulin levels and blood pressure were examined." | 3.69 | Metformin decreases plasma insulin levels and systolic blood pressure in spontaneously hypertensive rats. ( Bhanot, S; McNeill, JH; Verma, S, 1994) |
| "To determine whether improvement of insulin resistance decreases blood pressure as well as obesity, metformin (100 mg/kg/d) or vehicle was administered for 20 weeks to 12-week-old male Otsuka Long-Evans Tokushima Fatty (OLETF) rats (n = 10 each), a newly developed animal model of non-insulin-dependent diabetes mellitus (NIDDM) with mild obesity, hyperinsulinemia, and hypertriglyceridemia." | 3.69 | Metformin decreases blood pressure and obesity in OLETF rats via improvement of insulin resistance. ( Inukai, K; Ishii, J; Kashiwabara, H; Katayama, S; Kikuchi, C; Kosegawa, I; Negishi, K; Oka, Y, 1996) |
| "Metformin has been used as an oral anti-hyperglycaemic drug since the late 1950s; however, following the release in 1998 of the findings of the 20-year United Kingdom Prospective Diabetes Study (UKPDS), metformin use rapidly increased and today is the first-choice anti-hyperglycaemic drug for patients with type 2 diabetes (T2D)." | 3.01 | Repurposing Metformin for Vascular Disease. ( Anderson, TJ; Ding, H; Hill, MA; Hollenberg, MD; Marei, I; Triggle, CR; Ye, K, 2023) |
| "Metformin has become the focus of increased interest as a possible anti-ageing drug." | 3.01 | Mechanisms of ageing: growth hormone, dietary restriction, and metformin. ( Khan, J; Korbonits, M; Nisar, K; Pernicova, I, 2023) |
| "Metformin has been used clinically for more than 60 years." | 3.01 | The function, mechanisms, and clinical applications of metformin: potential drug, unlimited potentials. ( Deng, D; Liu, J; Zhang, M; Zhu, X, 2023) |
| "Metformin has been used for the treatment of type II diabetes mellitus for decades due to its safety, low cost, and outstanding hypoglycemic effect clinically." | 3.01 | The development and benefits of metformin in various diseases. ( Dong, Y; Jiang, H; Li, J; Li, W; Mi, T; Peng, C; Qi, Y; Zang, Y; Zhang, Y; Zhou, Y, 2023) |
| "Elderly subjects with metformin-treated type 2 diabetes have lower glucagon levels at 3." | 2.87 | Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes: A randomized, placebo-controlled study. ( Ahrén, B; Farngren, J; Persson, M, 2018) |
| "Aging is a natural process, which plays a critical role in the pathogenesis of a variety of diseases, i." | 2.82 | Metformin in aging and aging-related diseases: clinical applications and relevant mechanisms. ( Chen, M; Chen, S; Gan, D; Lin, S; Shao, Z; Xiao, G; Zhong, Y; Zou, X, 2022) |
| "Diseases such as Alzheimer's, type 2 diabetes mellitus (T2DM), Parkinson's, atherosclerosis, hypertension, and osteoarthritis are age-related, and most of these diseases are comorbidities or risk factors for AD; however, our understandings of molecular events that regulate the occurrence of these diseases are still not fully understood." | 2.82 | Importance of Bmal1 in Alzheimer's disease and associated aging-related diseases: Mechanisms and interventions. ( Chen, J; Dong, K; Fan, R; Ma, D; Peng, X; Shi, X; Xie, L; Xu, W; Yang, Y; Yu, X; Zhang, S, 2022) |
| "Management of hyperinsulinemia by pharmacological approaches, including metformin, sodium-glucose cotransporter 2 inhibitor, or β3-adrenergic receptor agonist, decreased GRP78 gene expression in adipose tissue." | 2.72 | Possible Involvement of Adipose Tissue in Patients With Older Age, Obesity, and Diabetes With SARS-CoV-2 Infection (COVID-19) via GRP78 (BIP/HSPA5): Significance of Hyperinsulinemia Management in COVID-19. ( Fukuhara, A; Kita, S; Nishitani, S; Otsuki, M; Shimomura, I; Shin, J; Toyoda, S, 2021) |
| "Metformin use can also reduce type 2 diabetes mellitus (T2DM) incidence among those at risk, lower cancer incidence, and improve cognitive function, cardiovascular disease (CVD) risk factors and atherosclerosis." | 2.72 | Targeting ageing and preventing organ degeneration with metformin. ( Sunjaya, AF; Sunjaya, AP, 2021) |
| " Patients were randomly assigned to sulphonylurea increased up to its maximum dosage (1st group) or to addition of metformin (2nd group)." | 2.69 | Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin. ( Ambrosi, F; Carle, F; Filipponi, P; Gregorio, F; Manfrini, S; Merante, D; Testa, R; Velussi, M, 1999) |
| "Metformin was clinically well-tolerated." | 2.68 | Is metformin safe enough for ageing type 2 diabetic patients? ( Ambrosi, F; Filipponi, P; Gregorio, F; Manfrini, S; Testa, I, 1996) |
| "Metformin is a safe, effective and useful drug for glucose management in patients with diabetes." | 2.66 | The Use of Metformin to Increase the Human Healthspan. ( Lushchak, O; Piskovatska, V; Storey, KB; Vaiserman, AM, 2020) |
| "Metformin is a widely used biguanide drug due to its safety and low cost." | 2.66 | Metformin and Its Benefits for Various Diseases. ( Guo, Y; Lv, Z, 2020) |
| "Mycophenolic acid was detected in all cats." | 2.61 | ( Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z, 2019) |
| "Metformin is a first-line therapy for type 2 diabetes." | 2.61 | Metformin: Mechanisms in Human Obesity and Weight Loss. ( Soukas, AA; Yerevanian, A, 2019) |
| "Cardiovascular diseases are the most prominent maladies in aging societies." | 2.58 | Autophagy in Cardiovascular Aging. ( Abdellatif, M; Carmona-Gutierrez, D; Kroemer, G; Madeo, F; Sedej, S, 2018) |
| "Metformin users also had reduced cancer compared to non-diabetics (rate ratio=0." | 2.55 | Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis. ( Bellman, SM; Campbell, JM; Lisy, K; Stephenson, MD, 2017) |
| "Although current therapies in chronic obstructive pulmonary disease (COPD) improve the quality of life, they do not satisfactorily reduce disease progression or mortality." | 2.55 | Geroprotectors as a therapeutic strategy for COPD - where are we now? ( Białas, AJ; Górski, P; Makowska, J; Miłkowska-Dymanowska, J; Piotrowski, WJ; Wardzynska, A, 2017) |
| "Fibrosis is a general term encompassing a plethora of pathologies that span all systems and is marked by increased deposition of collagen." | 2.53 | AMPK in cardiac fibrosis and repair: Actions beyond metabolic regulation. ( Beauloye, C; Bertrand, L; Daskalopoulos, EP; Dufeys, C; Horman, S, 2016) |
| "Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease of the lungs, which progresses very slowly and the majority of patients are therefore elderly." | 2.50 | STOP accelerating lung aging for the treatment of COPD. ( Ito, K; Mercado, N, 2014) |
| "Metformin is an AMPK agonist potentiating insulin actions in the adult human muscle, but not in the aged individuals." | 2.50 | Effects of the antidiabetic drugs on the age-related atrophy and sarcopenia associated with diabetes type II. ( Cetrone, M; Mele, A; Tricarico, D, 2014) |
| "Metformin has been described as a geroprotector, and several studies have shown that metformin can slow down the rate of aging." | 2.47 | Metformin as a geroprotector. ( Bulterijs, S, 2011) |
| "Furthermore metformin seems to decrease cancer risk in diabetic patients." | 2.46 | Metformin for aging and cancer prevention. ( Anisimov, VN, 2010) |
| "Metformin treatment showed a minor effect, while MV treatment did not improve any parameters." | 1.91 | Polyoxidovanadates as a pharmacological option against brain aging. ( Carreto-Meneses, K; Díaz, A; Moreno-Rodríguez, JA; Moroni-González, D; Treviño, S; Vázquez-Roque, R, 2023) |
| "Metformin is a biguanide widely used for glucose lowering, which is believed to have pleiotropic effects targeting several hallmarks of aging." | 1.91 | Drugs Targeting Mechanisms of Aging to Delay Age-Related Disease and Promote Healthspan: Proceedings of a National Institute on Aging Workshop. ( Baur, JA; de Cabo, R; Espinoza, SE; Khosla, S; Musi, N, 2023) |
| "Metformin, a clinical agent of type 2 diabetes, is reported as a potential geroprotector." | 1.72 | Metformin Protects Against Inflammation, Oxidative Stress to Delay Poly I:C-Induced Aging-Like Phenomena in the Gut of an Annual Fish. ( Hou, Y; Li, G; Li, S; Liu, K; Qiao, M; Sun, X; Zhu, H, 2022) |
| "Metformin is a widely used drug for treating type 2 diabetes and is also used for delaying sexual maturation in girls with precocious puberty." | 1.72 | Metformin treatment of juvenile mice alters aging-related developmental and metabolic phenotypes. ( Bartke, A; Fang, Y; Medina, D; Yuan, R; Zhu, Y, 2022) |
| "In addition, the benefits of metformin treatment of depression have been documented in a range of rodent studies and human trials, but few studies have probed into the effect of metformin on and the related mechanism in depressed elderly mice, especially in those APOE4 carriers." | 1.72 | Metformin alleviates the depression-like behaviors of elderly apoE4 mice via improving glucose metabolism and mitochondrial biogenesis. ( Chen, X; Dai, X; Lin, Y; Zhang, J, 2022) |
| "To evaluate the impact of type 2 diabetes (T2D) and obesity on COVID-19 severity, we conducted a cohort study with 28,095 anonymized COVID-19 patients using data from the COVID-19 Research Database from January 1, 2020 to November 30, 2020." | 1.62 | Impact of overlapping risks of type 2 diabetes and obesity on coronavirus disease severity in the United States. ( Ando, W; Atsuda, K; Hanaki, H; Horii, T; Otori, K; Uematsu, T, 2021) |
| "Aging is associated with central fat redistribution and insulin resistance." | 1.62 | Metformin alleviates stress-induced cellular senescence of aging human adipose stromal cells and the ensuing adipocyte dysfunction. ( Atlan, M; Auclair, M; Bereziat, V; Capeau, J; Fève, B; Foresti, R; Gorwood, J; Laforge, M; Lagathu, C; Le Pelletier, L; Mantecon, M; Motterlini, R, 2021) |
| "Metformin treatment also seemed to reduce astrocyte hypertrophy." | 1.62 | Metformin treatment in late middle age improves cognitive function with alleviation of microglial activation and enhancement of autophagy in the hippocampus. ( Attaluri, S; Gonzalez, JJ; Kodali, M; Madhu, LN; Rao, X; Shetty, AK; Shuai, B; Upadhya, R, 2021) |
| " This study aimed to evaluate the effects of long-term administration of metformin on age-dependent oxidative stress and cognitive function." | 1.62 | Long-term administration of metformin ameliorates age-dependent oxidative stress and cognitive function in rats. ( Baharvand, F; Gorgich, EAC; Parsaie, H; Sarbishegi, M; Yarmand, S, 2021) |
| "Low-grade inflammation is often higher in older adults and remains a key risk factor of aging-related morbidities and mortalities." | 1.56 | Metformin Reduces Aging-Related Leaky Gut and Improves Cognitive Function by Beneficially Modulating Gut Microbiome/Goblet Cell/Mucin Axis. ( Ahmadi, S; Ding, J; Jain, S; Justice, J; Kitzman, D; Kritchevsky, SB; McClain, DA; Mishra, SP; Nagpal, R; Razazan, A; Wang, B; Wang, S; Yadav, H, 2020) |
| "Metformin treatment caused astrocytes to alter reactive genes in a PD animal model." | 1.56 | Metformin regulates astrocyte reactivity in Parkinson's disease and normal aging. ( Choi, JH; Choi, YK; Go, J; Kim, KS; Lee, CH; Lee, TG; Park, HY; Rhee, M; Ryu, YK; Seo, YJ, 2020) |
| " In other words, which compounds are least likely to cause harm, while still potentially providing benefit? To systematically answer this question we queried the DrugAge database-containing hundreds of known geroprotectors-and cross-referenced this with a recently published repository of compound side effect predictions." | 1.56 | Identification of longevity compounds with minimized probabilities of side effects. ( Houtkooper, RH; Janssens, GE, 2020) |
| "We show that prediabetic serum hyperinsulinemia is reflected in the cerebrospinal fluid and that this chronically elevated insulin renders neurons resistant to insulin." | 1.51 | Age-related hyperinsulinemia leads to insulin resistance in neurons and cell-cycle-induced senescence. ( Chen, G; Cheng, A; Chow, HM; Gao, Y; Herrup, K; Shi, M; So, RWL; Song, X; Zhang, J, 2019) |
| "Hair loss or alopecia affects millions worldwide, but methods that can be used to regrow hair are lacking." | 1.51 | Stimulation of Hair Growth by Small Molecules that Activate Autophagy. ( Chai, M; Chu, J; Crooks, GM; de Barros, SC; Doan, NB; Fu, X; Herschman, H; Huang, J; Huang, W; Jiang, M; Jiao, J; Reue, K; Vergnes, L, 2019) |
| " In genetically heterogeneous HET3 mice, we found that chronic administration of encapsulated rapamycin by diet caused a measurable defect in glucose metabolism in both male and female mice as early as 1 month after treatment." | 1.48 | Metformin reduces glucose intolerance caused by rapamycin treatment in genetically heterogeneous female mice. ( Fernandez, E; Liu, Y; Salmon, AB; Strong, R; Weiss, R, 2018) |
| "Metformin has also recently been shown to beneficially alter gene splicing in normal humans." | 1.48 | Cellular stress and AMPK activation as a common mechanism of action linking the effects of metformin and diverse compounds that alleviate accelerated aging defects in Hutchinson-Gilford progeria syndrome. ( Finley, J, 2018) |
| "Treatment with metformin improved cardiovascular function and survival in mature animals of both genders." | 1.46 | Metformin ameliorates gender-and age-dependent hemodynamic instability and myocardial injury in murine hemorrhagic shock. ( Hake, PW; James, J; Lahni, P; Matsiukevich, D; O'Connor, M; Piraino, G; Wolfe, V; Zingarelli, B, 2017) |
| "Metformin treatment also decreased expression of the antioxidant pathway regulator, Nrf2." | 1.43 | Prolonged metformin treatment leads to reduced transcription of Nrf2 and neurotrophic factors without cognitive impairment in older C57BL/6J mice. ( Allard, JS; Carpenter, P; de Cabo, R; Fukui, K; Ingram, DK; Perez, EJ, 2016) |
| "Treatment with metformin altered the subcellular localization of AUF1, disrupting its interaction with DICER1 mRNA and rendering DICER1 mRNA stable, allowing DICER1 to accumulate." | 1.43 | Metformin-mediated increase in DICER1 regulates microRNA expression and cellular senescence. ( Becker, KG; Bernier, M; de Cabo, R; Dluzen, DF; Evans, MK; Gorospe, M; Martin-Montalvo, A; Noren Hooten, N; Zhang, Y; Zonderman, AB, 2016) |
| "Treatment with metformin also induced cell cycle arrest in UVC-induced cells, in correlation with a reduction in the levels of cyclin E/cdk2/Rb and cyclin B1/cdk1." | 1.43 | Combined metformin and resveratrol confers protection against UVC-induced DNA damage in A549 lung cancer cells via modulation of cell cycle checkpoints and DNA repair. ( Doonan, BB; Hsieh, TC; Lee, YS; Wu, JM, 2016) |
| "Metformin has utility in cancer prevention and treatment, though the mechanisms for these effects remain elusive." | 1.43 | An Ancient, Unified Mechanism for Metformin Growth Inhibition in C. elegans and Cancer. ( Carr, CE; Gygi, SP; Kacergis, MC; Li, M; Mou, F; Oshiro-Rapley, N; Paulo, JA; Soukas, AA; Talkowski, ME; Webster, CM; Wu, L; Zheng, B; Zhou, B, 2016) |
| "Metformin is an anti-type II diabetes drug that has anti-inflammatory and anti-oxidant properties, can bring about mitochondrial biogenesis and has been shown to attenuate pathology in mouse models of Huntington's disease and multiple sclerosis." | 1.37 | Metformin treatment has no beneficial effect in a dose-response survival study in the SOD1(G93A) mouse model of ALS and is harmful in female mice. ( Kaneb, HM; Rahmani-Kondori, N; Sharp, PS; Wells, DJ, 2011) |
| "The development of acute renal failure significantly complicates intravascular contrast medium (CM) use and is linked with high morbidity and mortality." | 1.34 | Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy. ( Barrett, B; Benko, A; Capusten, B; Fraser-Hill, M; Magner, P; Myers, A; Owen, RJ, 2007) |
| "The rising prevalence of pediatric type 2 diabetes mellitus (DM2) and non-adherence to diabetes regimens pose challenges to obtaining optimal control." | 1.33 | Predictors of metabolic control at one year in a population of pediatric patients with type 2 diabetes mellitus: a retrospective study. ( Alemzadeh, R; Calhoun, M; Ellis, J; Kichler, J, 2006) |
| "Glyburide did not lower DPP-IV activity or glycosylated hemoglobin." | 1.32 | Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. ( Croom, DK; Lenhard, JM; Minnick, DT, 2004) |
| " Metformin, administered at 200 mg/kg per os, ineffective dosage in normal mice, showed a strong hypoglycemic effect in younger mice (11--18 weeks) with a plasma IRI decrease and no blood lactate and liver glycogen alteration." | 1.26 | DBM mice as a pharmacological model of maturity onset diabetes. Studies with metformin. ( Brohon, J; Guillaume, M; Junien, JL; Sterne, J, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.49) | 18.7374 |
| 1990's | 6 (2.91) | 18.2507 |
| 2000's | 18 (8.74) | 29.6817 |
| 2010's | 107 (51.94) | 24.3611 |
| 2020's | 74 (35.92) | 2.80 |
| Authors | Studies |
|---|---|
| Hsu, SK | 1 |
| Cheng, KC | 1 |
| Mgbeahuruike, MO | 1 |
| Lin, YH | 1 |
| Wu, CY | 2 |
| Wang, HD | 1 |
| Yen, CH | 1 |
| Chiu, CC | 1 |
| Sheu, SJ | 1 |
| Ando, W | 1 |
| Horii, T | 1 |
| Uematsu, T | 1 |
| Hanaki, H | 1 |
| Atsuda, K | 1 |
| Otori, K | 1 |
| Hong, S | 1 |
| Nagayach, A | 1 |
| Lu, Y | 1 |
| Peng, H | 1 |
| Duong, QA | 1 |
| Pham, NB | 1 |
| Vuong, CA | 1 |
| Bazan, NG | 1 |
| Verdurmen, WPR | 1 |
| Le Pelletier, L | 1 |
| Mantecon, M | 1 |
| Gorwood, J | 1 |
| Auclair, M | 1 |
| Foresti, R | 1 |
| Motterlini, R | 1 |
| Laforge, M | 1 |
| Atlan, M | 1 |
| Fève, B | 1 |
| Capeau, J | 1 |
| Lagathu, C | 1 |
| Bereziat, V | 1 |
| Shin, J | 1 |
| Toyoda, S | 1 |
| Nishitani, S | 1 |
| Fukuhara, A | 1 |
| Kita, S | 1 |
| Otsuki, M | 1 |
| Shimomura, I | 1 |
| Li, S | 2 |
| Hou, Y | 1 |
| Liu, K | 1 |
| Zhu, H | 1 |
| Qiao, M | 1 |
| Sun, X | 1 |
| Li, G | 1 |
| Starling, S | 1 |
| Efentakis, P | 1 |
| Psarakou, G | 1 |
| Varela, A | 1 |
| Papanagnou, ED | 1 |
| Chatzistefanou, M | 1 |
| Nikolaou, PE | 1 |
| Davos, CH | 1 |
| Gavriatopoulou, M | 1 |
| Trougakos, IP | 1 |
| Dimopoulos, MA | 1 |
| Andreadou, I | 1 |
| Terpos, E | 1 |
| Herbst, A | 1 |
| Hoang, A | 1 |
| Kim, C | 1 |
| Aiken, JM | 1 |
| McKenzie, D | 1 |
| Goldwater, DS | 1 |
| Wanagat, J | 1 |
| Zhu, Y | 1 |
| Fang, Y | 1 |
| Medina, D | 1 |
| Bartke, A | 1 |
| Yuan, R | 1 |
| Onken, B | 1 |
| Sedore, CA | 1 |
| Coleman-Hulbert, AL | 1 |
| Hall, D | 1 |
| Johnson, E | 1 |
| Jones, EG | 1 |
| Banse, SA | 1 |
| Huynh, P | 1 |
| Guo, S | 1 |
| Xue, J | 1 |
| Chen, E | 1 |
| Harinath, G | 1 |
| Foulger, AC | 1 |
| Chao, EA | 1 |
| Hope, J | 1 |
| Bhaumik, D | 1 |
| Plummer, T | 1 |
| Inman, D | 1 |
| Morshead, M | 1 |
| Guo, M | 1 |
| Lithgow, GJ | 1 |
| Phillips, PC | 1 |
| Driscoll, M | 1 |
| Kumari, S | 1 |
| Bubak, MT | 1 |
| Schoenberg, HM | 1 |
| Davidyan, A | 1 |
| Elliehausen, CJ | 1 |
| Kuhn, KG | 1 |
| VanWagoner, TM | 1 |
| Karaman, R | 1 |
| Scofield, RH | 1 |
| Miller, BF | 2 |
| Konopka, AR | 2 |
| Nwanaji-Enwerem, JC | 1 |
| Chung, FF | 1 |
| Van der Laan, L | 1 |
| Novoloaca, A | 1 |
| Cuenin, C | 1 |
| Johansson, H | 1 |
| Bonanni, B | 1 |
| Hubbard, AE | 1 |
| Smith, MT | 1 |
| Hartman, SJ | 1 |
| Cardenas, A | 1 |
| Sears, DD | 1 |
| Herceg, Z | 1 |
| Howlett, LA | 1 |
| Jones, SA | 1 |
| Lancaster, MK | 1 |
| Lin, Y | 2 |
| Dai, X | 2 |
| Zhang, J | 6 |
| Chen, X | 5 |
| Song, H | 3 |
| Zhang, X | 4 |
| Zhai, R | 1 |
| Liang, H | 1 |
| Song, G | 1 |
| Yuan, Y | 1 |
| Xu, Y | 1 |
| Yan, Y | 1 |
| Qiu, L | 1 |
| Sun, T | 1 |
| Żyrek, L | 1 |
| Latocha, M | 1 |
| Rempuia, V | 1 |
| Anima, B | 1 |
| Jeremy, M | 1 |
| Gurusubramanian, G | 1 |
| Pankaj, PP | 1 |
| Kharwar, RK | 1 |
| Roy, VK | 1 |
| Yang, SP | 1 |
| Su, Q | 1 |
| Zhang, YR | 1 |
| Sun, Y | 1 |
| Chai, YR | 1 |
| Chen, S | 1 |
| Gan, D | 1 |
| Lin, S | 1 |
| Zhong, Y | 1 |
| Chen, M | 2 |
| Zou, X | 1 |
| Shao, Z | 1 |
| Xiao, G | 1 |
| Antal, B | 1 |
| McMahon, LP | 1 |
| Sultan, SF | 1 |
| Lithen, A | 1 |
| Wexler, DJ | 1 |
| Dickerson, B | 1 |
| Ratai, EM | 1 |
| Mujica-Parodi, LR | 1 |
| Triggle, CR | 2 |
| Marei, I | 1 |
| Ye, K | 2 |
| Ding, H | 2 |
| Anderson, TJ | 1 |
| Hollenberg, MD | 2 |
| Hill, MA | 1 |
| Müller-Werdan, U | 1 |
| Fan, R | 1 |
| Peng, X | 1 |
| Xie, L | 1 |
| Dong, K | 1 |
| Ma, D | 1 |
| Xu, W | 1 |
| Shi, X | 1 |
| Zhang, S | 3 |
| Chen, J | 2 |
| Yu, X | 1 |
| Yang, Y | 1 |
| Ameen, O | 1 |
| Samaka, RM | 1 |
| Abo-Elsoud, RAA | 1 |
| Brown, R | 1 |
| Hogan, MV | 1 |
| Onishi, K | 1 |
| Wang, JH | 1 |
| Xenos, D | 1 |
| Mecocci, P | 1 |
| Boccardi, V | 1 |
| Parish, AJ | 1 |
| Swindell, WR | 1 |
| Culig, L | 1 |
| Sahbaz, BD | 1 |
| Bohr, VA | 1 |
| Suzuta, S | 3 |
| Nishida, H | 3 |
| Ozaki, M | 3 |
| Kohno, N | 3 |
| Le, TD | 3 |
| Inoue, YH | 3 |
| Thanapairoje, K | 1 |
| Junsiritrakhoon, S | 1 |
| Wichaiyo, S | 1 |
| Osman, MA | 1 |
| Supharattanasitthi, W | 1 |
| Marra, PS | 1 |
| Yamanashi, T | 1 |
| Crutchley, KJ | 1 |
| Wahba, NE | 1 |
| Anderson, ZM | 1 |
| Modukuri, M | 1 |
| Chang, G | 1 |
| Tran, T | 1 |
| Iwata, M | 1 |
| Cho, HR | 1 |
| Shinozaki, G | 1 |
| Khan, J | 1 |
| Pernicova, I | 1 |
| Nisar, K | 1 |
| Korbonits, M | 1 |
| Choi, J | 1 |
| Houston, M | 1 |
| Wang, R | 1 |
| Li, W | 2 |
| Huffman, DM | 2 |
| Augenlicht, LH | 1 |
| Dai, G | 1 |
| Li, Y | 6 |
| Zhang, M | 3 |
| Lu, P | 1 |
| Zhang, Y | 9 |
| Wang, H | 2 |
| Shi, L | 1 |
| Cao, M | 1 |
| Shen, R | 1 |
| Rui, Y | 1 |
| Díaz, A | 1 |
| Vázquez-Roque, R | 1 |
| Carreto-Meneses, K | 1 |
| Moroni-González, D | 1 |
| Moreno-Rodríguez, JA | 1 |
| Treviño, S | 1 |
| Liu, J | 5 |
| Deng, D | 1 |
| Zhu, X | 1 |
| Espinoza, SE | 2 |
| Khosla, S | 1 |
| Baur, JA | 2 |
| de Cabo, R | 4 |
| Musi, N | 1 |
| Dong, Y | 1 |
| Qi, Y | 1 |
| Jiang, H | 1 |
| Mi, T | 1 |
| Peng, C | 1 |
| Zhou, Y | 1 |
| Zang, Y | 1 |
| Li, J | 7 |
| Tezze, C | 1 |
| Amendolagine, FI | 1 |
| Nogara, L | 1 |
| Baraldo, M | 1 |
| Ciciliot, S | 1 |
| Arcidiacono, D | 1 |
| Zaramella, A | 1 |
| Masiero, G | 1 |
| Ferrarese, G | 1 |
| Realdon, S | 1 |
| Blaauw, B | 1 |
| Detienne, G | 1 |
| Beliën, AT | 1 |
| Sandri, M | 1 |
| Mercken, EM | 1 |
| Asghari, F | 1 |
| Karimi, MH | 1 |
| Pourfathollah, AA | 1 |
| Soukas, AA | 3 |
| Hao, H | 1 |
| Wu, L | 4 |
| Bobenko, AI | 1 |
| Heller, S | 1 |
| Schmitt, N | 1 |
| Cherdtrakulkiat, R | 1 |
| Lawung, R | 1 |
| Nabu, S | 1 |
| Tantimavanich, S | 1 |
| Sinthupoom, N | 1 |
| Prachayasittikul, S | 1 |
| Prachayasittikul, V | 1 |
| Zhang, B | 1 |
| Wu, C | 1 |
| Zhang, Z | 2 |
| Yan, K | 1 |
| Li, C | 3 |
| Li, L | 3 |
| Zheng, C | 1 |
| Xiao, Y | 1 |
| He, D | 1 |
| Zhao, F | 1 |
| Su, JF | 1 |
| Lun, SM | 1 |
| Hou, YJ | 1 |
| Duan, LJ | 1 |
| Wang, NC | 1 |
| Shen, FF | 1 |
| Zhang, YW | 1 |
| Gao, ZW | 1 |
| Du, XJ | 1 |
| Zhou, FY | 1 |
| Yin, Z | 1 |
| Zhu, J | 2 |
| Yan, D | 1 |
| Lou, H | 1 |
| Yu, H | 1 |
| Feng, C | 1 |
| Wang, Z | 1 |
| Wang, Y | 5 |
| Hu, X | 1 |
| Li, Z | 4 |
| Shen, Y | 1 |
| Hu, D | 1 |
| Chen, H | 1 |
| Wu, X | 2 |
| Duan, Y | 1 |
| Zhi, D | 1 |
| Zou, M | 2 |
| Zhao, Z | 1 |
| Yang, X | 3 |
| Popović, KJ | 1 |
| Popović, DJ | 1 |
| Miljković, D | 1 |
| Lalošević, D | 1 |
| Čapo, I | 1 |
| Popović, JK | 1 |
| Liu, M | 2 |
| Xing, Z | 1 |
| Lu, G | 1 |
| Chen, D | 1 |
| Valentini, AM | 1 |
| Di Pinto, F | 1 |
| Coletta, S | 1 |
| Guerra, V | 1 |
| Armentano, R | 1 |
| Caruso, ML | 1 |
| Gong, J | 1 |
| Wang, N | 1 |
| Bian, L | 1 |
| Wang, M | 1 |
| Ye, M | 1 |
| Wen, N | 1 |
| Fu, M | 1 |
| Fan, W | 1 |
| Meng, Y | 1 |
| Dong, G | 1 |
| Lin, XH | 1 |
| Liu, HH | 1 |
| Gao, DM | 1 |
| Cui, JF | 1 |
| Ren, ZG | 1 |
| Chen, RX | 1 |
| Önal, B | 1 |
| Özen, D | 1 |
| Demir, B | 1 |
| Akkan, AG | 1 |
| Özyazgan, S | 1 |
| Payette, G | 1 |
| Geoffroy, V | 1 |
| Martineau, C | 1 |
| Villemur, R | 1 |
| Jameel, T | 1 |
| Baig, M | 1 |
| Gazzaz, ZJ | 1 |
| Tashkandi, JM | 1 |
| Al Alhareth, NS | 1 |
| Khan, SA | 1 |
| Butt, NS | 1 |
| Wang, J | 3 |
| Geng, Y | 1 |
| Wang, X | 3 |
| Basit, A | 1 |
| Miao, T | 1 |
| Liu, W | 1 |
| Jiang, W | 1 |
| Yu, ZY | 1 |
| Qu, B | 1 |
| Sun, JX | 1 |
| Cai, AL | 1 |
| Xie, LM | 1 |
| Groeneveld, J | 1 |
| Ho, SL | 1 |
| Mackensen, A | 1 |
| Mohtadi, M | 1 |
| Laepple, T | 1 |
| Genovesi, S | 1 |
| Nava, E | 1 |
| Bartolucci, C | 1 |
| Severi, S | 1 |
| Vincenti, A | 1 |
| Contaldo, G | 1 |
| Bigatti, G | 1 |
| Ciurlino, D | 1 |
| Bertoli, SV | 1 |
| Slovak, JE | 1 |
| Hwang, JK | 1 |
| Rivera, SM | 1 |
| Villarino, NF | 1 |
| Cao, G | 1 |
| Ling, M | 1 |
| Ji, J | 1 |
| Zhao, D | 1 |
| Sha, Y | 1 |
| Gao, X | 1 |
| Liang, C | 2 |
| Guo, Q | 1 |
| Zhou, C | 1 |
| Ma, Z | 1 |
| Xu, J | 1 |
| Wang, C | 1 |
| Zhao, W | 1 |
| Xia, X | 1 |
| Jiang, Y | 1 |
| Peng, J | 1 |
| Jia, Z | 1 |
| Li, F | 1 |
| Mo, J | 1 |
| Li, X | 2 |
| Huang, T | 1 |
| Zhu, Q | 1 |
| Wang, S | 2 |
| Ge, RS | 1 |
| Fortunato, G | 1 |
| Lin, J | 2 |
| Agarwal, PK | 1 |
| Kohen, A | 1 |
| Singh, P | 1 |
| Cheatum, CM | 1 |
| Zhu, D | 1 |
| Hayman, A | 1 |
| Kebede, B | 1 |
| Stewart, I | 1 |
| Chen, G | 2 |
| Frew, R | 1 |
| Guo, X | 1 |
| Gong, Q | 1 |
| Borowiec, J | 1 |
| Han, S | 1 |
| Willis, M | 1 |
| Kreouzis, T | 1 |
| Yu, K | 1 |
| Chirvony, VS | 1 |
| Sekerbayev, KS | 1 |
| Pérez-Del-Rey, D | 1 |
| Martínez-Pastor, JP | 1 |
| Palazon, F | 1 |
| Boix, PP | 1 |
| Taurbayev, TI | 1 |
| Sessolo, M | 1 |
| Bolink, HJ | 1 |
| Lu, M | 1 |
| Lan, Y | 1 |
| Xiao, J | 1 |
| Song, M | 1 |
| Chen, C | 2 |
| Huang, Q | 2 |
| Cao, Y | 1 |
| Ho, CT | 1 |
| Qi, B | 1 |
| Wang, Q | 2 |
| Zhang, W | 1 |
| Fang, L | 1 |
| Xie, CL | 1 |
| Chen, R | 1 |
| Yang, S | 1 |
| Xia, JM | 1 |
| Zhang, GY | 1 |
| Chen, CH | 1 |
| Yang, XW | 1 |
| Domenech-Ximenos, B | 1 |
| Garza, MS | 1 |
| Prat-González, S | 1 |
| Sepúlveda-Martínez, Á | 1 |
| Crispi, F | 1 |
| Perea, RJ | 1 |
| Garcia-Alvarez, A | 1 |
| Sitges, M | 1 |
| Kalumpha, M | 1 |
| Guyo, U | 1 |
| Zinyama, NP | 1 |
| Vakira, FM | 1 |
| Nyamunda, BC | 1 |
| Varga, M | 1 |
| Drácz, L | 1 |
| Kolbenheyer, E | 1 |
| Varga, F | 1 |
| Patai, ÁV | 1 |
| Solymosi, N | 1 |
| Patai, Á | 1 |
| Kiss, J | 1 |
| Gaál, V | 1 |
| Nyul, Z | 1 |
| Mosdósi, B | 1 |
| Valdez, M | 1 |
| Moosavi, L | 1 |
| Heidari, A | 1 |
| Novakovic-Agopian, T | 1 |
| Kornblith, E | 1 |
| Abrams, G | 1 |
| McQuaid, JR | 1 |
| Posecion, L | 1 |
| Burciaga, J | 1 |
| D'Esposito, M | 1 |
| Chen, AJW | 1 |
| Samy El Gendy, NM | 1 |
| Wesolowska, P | 1 |
| Georg, D | 1 |
| Lechner, W | 1 |
| Kazantsev, P | 1 |
| Bokulic, T | 1 |
| Tedgren, AC | 1 |
| Adolfsson, E | 1 |
| Campos, AM | 1 |
| Alves, VGL | 1 |
| Suming, L | 1 |
| Hao, W | 1 |
| Ekendahl, D | 1 |
| Koniarova, I | 1 |
| Bulski, W | 1 |
| Chelminski, K | 1 |
| Samper, JLA | 1 |
| Vinatha, SP | 1 |
| Rakshit, S | 1 |
| Siri, S | 1 |
| Tomsejm, M | 1 |
| Tenhunen, M | 1 |
| Povall, J | 1 |
| Kry, SF | 1 |
| Followill, DS | 1 |
| Thwaites, DI | 1 |
| Izewska, J | 1 |
| Kang, JH | 1 |
| Yoon, Y | 1 |
| Song, J | 1 |
| Van de Winckel, A | 1 |
| Gauthier, L | 1 |
| Chao, CT | 1 |
| Lee, YH | 1 |
| Li, CM | 1 |
| Han, DS | 1 |
| Huang, JW | 1 |
| Huang, KC | 1 |
| Ni, L | 1 |
| Güttinger, R | 1 |
| Triana, CA | 1 |
| Spingler, B | 1 |
| Baldridge, KK | 1 |
| Patzke, GR | 1 |
| Shen, X | 1 |
| Wang, B | 2 |
| Xie, S | 1 |
| Deng, W | 1 |
| Wu, D | 1 |
| Zhang, Q | 1 |
| Voskamp, BJ | 1 |
| Peelen, MJCS | 1 |
| Ravelli, ACJ | 1 |
| van der Lee, R | 1 |
| Mol, BWJ | 1 |
| Pajkrt, E | 1 |
| Ganzevoort, W | 1 |
| Kazemier, BM | 1 |
| Tibrewala, R | 1 |
| Bahroos, E | 1 |
| Mehrabian, H | 1 |
| Foreman, SC | 1 |
| Link, TM | 1 |
| Pedoia, V | 1 |
| Majumdar, S | 1 |
| Jablonski, CL | 1 |
| Leonard, C | 1 |
| Salo, P | 1 |
| Krawetz, RJ | 1 |
| Yoon, N | 1 |
| Hong, SN | 1 |
| Cho, JG | 1 |
| Jeong, HK | 1 |
| Lee, KH | 1 |
| Park, HW | 1 |
| Barman, S | 1 |
| Konai, MM | 1 |
| Samaddar, S | 1 |
| Haldar, J | 1 |
| Mohamed, HSH | 1 |
| Li, CF | 1 |
| Hu, ZY | 1 |
| Deng, Z | 1 |
| Chen, LH | 1 |
| Su, BL | 1 |
| Chu, K | 1 |
| Liu, YP | 1 |
| Li, YB | 1 |
| Zhang, H | 1 |
| Xu, C | 1 |
| Zou, Z | 1 |
| Wu, Z | 1 |
| Xia, Y | 1 |
| Zhao, P | 3 |
| Wang, HT | 1 |
| de Biase, S | 1 |
| Pellitteri, G | 1 |
| Gigli, GL | 1 |
| Valente, M | 1 |
| Glossmann, HH | 1 |
| Lutz, OMD | 1 |
| Neumann, B | 1 |
| Baror, R | 1 |
| Zhao, C | 1 |
| Segel, M | 1 |
| Dietmann, S | 1 |
| Rawji, KS | 1 |
| Foerster, S | 1 |
| McClain, CR | 1 |
| Chalut, K | 1 |
| van Wijngaarden, P | 1 |
| Franklin, RJM | 1 |
| de Grey, ADNJ | 1 |
| Chow, HM | 1 |
| Shi, M | 1 |
| Cheng, A | 1 |
| Gao, Y | 1 |
| Song, X | 1 |
| So, RWL | 1 |
| Herrup, K | 1 |
| Cheng, J | 2 |
| Lu, MM | 1 |
| Gao, LY | 1 |
| Jiang, HX | 1 |
| Liu, P | 1 |
| Huang, XW | 1 |
| Liu, YL | 1 |
| Cai, H | 1 |
| Han, B | 1 |
| Hu, Y | 1 |
| Zhao, X | 1 |
| He, Z | 1 |
| Sun, H | 1 |
| Yuan, J | 1 |
| Kong, W | 1 |
| Kong, WJ | 1 |
| Mu, N | 1 |
| Gu, C | 1 |
| Yang, Z | 1 |
| Yin, Y | 1 |
| Han, Y | 1 |
| Yu, L | 1 |
| Ma, H | 1 |
| Ahmadi, S | 1 |
| Razazan, A | 1 |
| Nagpal, R | 1 |
| Jain, S | 1 |
| Mishra, SP | 1 |
| Justice, J | 1 |
| Ding, J | 1 |
| McClain, DA | 1 |
| Kritchevsky, SB | 3 |
| Kitzman, D | 1 |
| Yadav, H | 1 |
| Piskovatska, V | 2 |
| Storey, KB | 2 |
| Vaiserman, AM | 2 |
| Lushchak, O | 2 |
| Kulkarni, AS | 2 |
| Gubbi, S | 1 |
| Barzilai, N | 5 |
| Liu, B | 1 |
| Huang, B | 1 |
| Shi, JS | 1 |
| Kroemer, G | 3 |
| Zitvogel, L | 1 |
| Bharath, LP | 2 |
| Agrawal, M | 1 |
| McCambridge, G | 1 |
| Nicholas, DA | 1 |
| Hasturk, H | 1 |
| Jiang, K | 1 |
| Liu, R | 1 |
| Guo, Z | 1 |
| Deeney, J | 1 |
| Apovian, CM | 1 |
| Snyder-Cappione, J | 1 |
| Hawk, GS | 1 |
| Fleeman, RM | 1 |
| Pihl, RMF | 1 |
| Thompson, K | 1 |
| Belkina, AC | 1 |
| Cui, L | 1 |
| Proctor, EA | 1 |
| Kern, PA | 2 |
| Nikolajczyk, BS | 2 |
| Lv, Z | 1 |
| Guo, Y | 1 |
| Ryu, YK | 1 |
| Go, J | 1 |
| Park, HY | 1 |
| Choi, YK | 1 |
| Seo, YJ | 1 |
| Choi, JH | 1 |
| Rhee, M | 1 |
| Lee, TG | 1 |
| Lee, CH | 1 |
| Kim, KS | 1 |
| Janssens, GE | 1 |
| Houtkooper, RH | 1 |
| Torres, W | 1 |
| Nava, M | 1 |
| Galbán, N | 1 |
| Gómez, Y | 1 |
| Morillo, V | 1 |
| Rojas, M | 1 |
| Cano, C | 1 |
| Chacín, M | 1 |
| D Marco, L | 1 |
| Herazo, Y | 1 |
| Velasco, M | 1 |
| Bermúdez, V | 1 |
| Rojas-Quintero, J | 1 |
| Ouk, M | 1 |
| Wong, YY | 1 |
| Anita, NZ | 1 |
| Edwards, JD | 1 |
| Yang, P | 1 |
| Shah, BR | 1 |
| Herrmann, N | 1 |
| Lanctôt, KL | 1 |
| Kapral, MK | 1 |
| MacIntosh, BJ | 1 |
| Rabin, JS | 1 |
| Black, SE | 1 |
| Swardfager, W | 1 |
| Zajda, A | 1 |
| Huttunen, KM | 1 |
| Sikora, J | 1 |
| Podsiedlik, M | 1 |
| Markowicz-Piasecka, M | 1 |
| Willyard, C | 1 |
| Espada, L | 1 |
| Dakhovnik, A | 1 |
| Chaudhari, P | 1 |
| Martirosyan, A | 1 |
| Miek, L | 1 |
| Poliezhaieva, T | 1 |
| Schaub, Y | 1 |
| Nair, A | 1 |
| Döring, N | 1 |
| Rahnis, N | 1 |
| Werz, O | 1 |
| Koeberle, A | 1 |
| Kirkpatrick, J | 1 |
| Ori, A | 1 |
| Ermolaeva, MA | 1 |
| Sunjaya, AP | 1 |
| Sunjaya, AF | 1 |
| Kodali, M | 1 |
| Attaluri, S | 1 |
| Madhu, LN | 1 |
| Shuai, B | 1 |
| Upadhya, R | 1 |
| Gonzalez, JJ | 1 |
| Rao, X | 1 |
| Shetty, AK | 1 |
| Chang, YC | 1 |
| Hee, SW | 1 |
| Chuang, LM | 1 |
| Sharma, S | 1 |
| Nozohouri, S | 1 |
| Vaidya, B | 1 |
| Abbruscato, T | 1 |
| Violante-Cumpa, JR | 1 |
| Pérez-Arredondo, LA | 1 |
| González-González, JG | 1 |
| Mancillas-Adame, LG | 1 |
| Samaras, K | 1 |
| Crawford, JD | 1 |
| Draper, B | 1 |
| Trollor, JN | 1 |
| Brodaty, H | 1 |
| Sachdev, PS | 1 |
| Su, YJ | 1 |
| Wang, PW | 1 |
| Weng, SW | 1 |
| Prattichizzo, F | 2 |
| Sabbatinelli, J | 2 |
| de Candia, P | 1 |
| Olivieri, F | 2 |
| Ceriello, A | 2 |
| Gorgich, EAC | 1 |
| Parsaie, H | 1 |
| Yarmand, S | 1 |
| Baharvand, F | 1 |
| Sarbishegi, M | 1 |
| Garay, RP | 1 |
| Nie, L | 1 |
| Yue, Z | 1 |
| Zhang, P | 1 |
| Ji, N | 1 |
| Chen, Q | 1 |
| Petrache, I | 1 |
| Serban, KA | 1 |
| Petrocelli, JJ | 1 |
| Mahmassani, ZS | 1 |
| Fix, DK | 1 |
| Montgomery, JA | 1 |
| Reidy, PT | 1 |
| McKenzie, AI | 1 |
| de Hart, NM | 1 |
| Ferrara, PJ | 1 |
| Kelley, JJ | 1 |
| Eshima, H | 1 |
| Funai, K | 1 |
| Drummond, MJ | 1 |
| Mohammed, I | 1 |
| Induri, SNR | 1 |
| Kansara, P | 1 |
| Thomas, SC | 1 |
| Xu, F | 1 |
| Saxena, D | 1 |
| Stockinger, J | 1 |
| Maxwell, N | 1 |
| Shapiro, D | 1 |
| deCabo, R | 1 |
| Valdez, G | 1 |
| Long, DE | 1 |
| Peck, BD | 1 |
| Martz, JL | 1 |
| Tuggle, SC | 1 |
| Bush, HM | 1 |
| McGwin, G | 1 |
| Bamman, MM | 1 |
| Peterson, CA | 1 |
| Crutchfield, P | 1 |
| Singh, AK | 3 |
| Garg, G | 3 |
| Singh, S | 3 |
| Rizvi, SI | 3 |
| Khan, SS | 1 |
| Singer, BD | 1 |
| Vaughan, DE | 1 |
| Barger, JL | 1 |
| Vann, JM | 1 |
| Cray, NL | 1 |
| Pugh, TD | 1 |
| Mastaloudis, A | 1 |
| Hester, SN | 1 |
| Wood, SM | 1 |
| Newton, MA | 1 |
| Weindruch, R | 1 |
| Prolla, TA | 1 |
| Matsiukevich, D | 1 |
| Piraino, G | 1 |
| Lahni, P | 1 |
| Hake, PW | 1 |
| Wolfe, V | 1 |
| O'Connor, M | 1 |
| James, J | 1 |
| Zingarelli, B | 1 |
| Sui, BD | 1 |
| Liu, N | 1 |
| Lv, YJ | 1 |
| Zheng, CX | 1 |
| Lu, YB | 1 |
| Huang, WT | 1 |
| Zhou, CH | 1 |
| Pang, DL | 1 |
| Fei, DD | 1 |
| Xuan, K | 1 |
| Hu, CH | 1 |
| Jin, Y | 1 |
| Reddy, SSK | 1 |
| Chaiban, JT | 1 |
| Valencia, WM | 1 |
| Palacio, A | 1 |
| Tamariz, L | 1 |
| Florez, H | 1 |
| Campbell, JM | 1 |
| Bellman, SM | 1 |
| Stephenson, MD | 1 |
| Lisy, K | 1 |
| Kenawy, S | 1 |
| Hegazy, R | 1 |
| Hassan, A | 1 |
| El-Shenawy, S | 1 |
| Gomaa, N | 1 |
| Zaki, H | 1 |
| Attia, A | 1 |
| Wang, YW | 1 |
| He, SJ | 1 |
| Feng, X | 1 |
| Luo, YT | 1 |
| Tian, L | 1 |
| Miłkowska-Dymanowska, J | 1 |
| Białas, AJ | 1 |
| Makowska, J | 1 |
| Wardzynska, A | 1 |
| Górski, P | 1 |
| Piotrowski, WJ | 1 |
| Savage, N | 1 |
| Brutsaert, EF | 1 |
| Anghel, V | 1 |
| Zhang, K | 1 |
| Bloomgarden, N | 1 |
| Pollak, M | 2 |
| Mar, JC | 1 |
| Hawkins, M | 1 |
| Crandall, JP | 2 |
| Fatemi, I | 2 |
| Heydari, S | 1 |
| Kaeidi, A | 2 |
| Shamsizadeh, A | 1 |
| Hakimizadeh, E | 2 |
| Khaluoi, A | 1 |
| Allahtavakoli, M | 2 |
| Weiss, R | 1 |
| Fernandez, E | 1 |
| Liu, Y | 1 |
| Strong, R | 1 |
| Salmon, AB | 1 |
| Farngren, J | 1 |
| Persson, M | 1 |
| Ahrén, B | 1 |
| Verspohl, E | 1 |
| Finley, J | 1 |
| Nikolakopoulou, P | 1 |
| Chatzigeorgiou, A | 1 |
| Kourtzelis, I | 1 |
| Toutouna, L | 1 |
| Masjkur, J | 1 |
| Arps-Forker, C | 1 |
| Poser, SW | 1 |
| Rozman, J | 1 |
| Rathkolb, B | 1 |
| Aguilar-Pimentel, JA | 1 |
| Wolf, E | 1 |
| Klingenspor, M | 1 |
| Ollert, M | 1 |
| Schmidt-Weber, C | 1 |
| Fuchs, H | 1 |
| Gailus-Durner, V | 1 |
| Hrabe de Angelis, M | 1 |
| Tsata, V | 1 |
| Monasor, LS | 1 |
| Troullinaki, M | 1 |
| Witt, A | 1 |
| Anastasiou, V | 1 |
| Chrousos, G | 1 |
| Yi, CX | 1 |
| García-Cáceres, C | 1 |
| Tschöp, MH | 1 |
| Bornstein, SR | 1 |
| Androutsellis-Theotokis, A | 1 |
| Mullard, A | 1 |
| Justice, JN | 1 |
| Ferrucci, L | 1 |
| Newman, AB | 1 |
| Aroda, VR | 1 |
| Bahnson, JL | 1 |
| Divers, J | 1 |
| Espeland, MA | 2 |
| Marcovina, S | 1 |
| Pollak, MN | 1 |
| Kuchel, GA | 1 |
| Belloni, L | 1 |
| Di Cocco, S | 1 |
| Guerrieri, F | 1 |
| Nunn, ADG | 1 |
| Piconese, S | 1 |
| Salerno, D | 1 |
| Testoni, B | 1 |
| Pulito, C | 1 |
| Mori, F | 1 |
| Pallocca, M | 1 |
| Sacconi, A | 1 |
| Vivoli, E | 1 |
| Marra, F | 1 |
| Strano, S | 1 |
| Blandino, G | 1 |
| Levrero, M | 1 |
| Pediconi, N | 1 |
| Stefanyshyn, N | 1 |
| Admasu, TD | 1 |
| Chaithanya Batchu, K | 1 |
| Barardo, D | 1 |
| Ng, LF | 1 |
| Lam, VYM | 1 |
| Xiao, L | 1 |
| Cazenave-Gassiot, A | 1 |
| Wenk, MR | 1 |
| Tolwinski, NS | 1 |
| Gruber, J | 1 |
| Giuliani, A | 1 |
| Mensà, E | 1 |
| De Nigris, V | 1 |
| Rippo, MR | 1 |
| La Sala, L | 1 |
| Procopio, AD | 1 |
| Abdellatif, M | 1 |
| Sedej, S | 1 |
| Carmona-Gutierrez, D | 1 |
| Madeo, F | 2 |
| Rahimi, VB | 1 |
| Askari, VR | 2 |
| Mousavi, SH | 2 |
| Wang, SY | 1 |
| Cai, GY | 2 |
| Chen, XM | 2 |
| Hang, L | 1 |
| Thundyil, J | 1 |
| Goh, GWY | 1 |
| Lim, KL | 1 |
| Hillson, O | 1 |
| Gonzalez, S | 1 |
| Rallis, C | 1 |
| Kanigur Sultuybek, G | 1 |
| Soydas, T | 1 |
| Yenmis, G | 1 |
| Yerevanian, A | 1 |
| Fang, W | 1 |
| Watson, LE | 1 |
| Xie, C | 1 |
| Phillips, LK | 1 |
| Sun, Z | 1 |
| Jones, KL | 1 |
| Horowitz, M | 1 |
| Rayner, CK | 1 |
| Wu, T | 1 |
| Chai, M | 1 |
| Jiang, M | 1 |
| Vergnes, L | 1 |
| Fu, X | 1 |
| de Barros, SC | 1 |
| Doan, NB | 1 |
| Huang, W | 1 |
| Chu, J | 1 |
| Jiao, J | 1 |
| Herschman, H | 1 |
| Crooks, GM | 1 |
| Reue, K | 1 |
| Huang, J | 1 |
| Baradaran Rahimi, V | 1 |
| Zakeri, M | 1 |
| Zakeri, MA | 1 |
| Hassanipour, M | 1 |
| Rahmani, M | 1 |
| Hassanshahi, J | 1 |
| Ayoobi, F | 1 |
| Lamming, DW | 1 |
| Ye, L | 1 |
| Sabatini, DM | 1 |
| Menendez, JA | 2 |
| Joven, J | 2 |
| Cabreiro, F | 1 |
| Au, C | 1 |
| Leung, KY | 1 |
| Vergara-Irigaray, N | 1 |
| Cochemé, HM | 1 |
| Noori, T | 1 |
| Weinkove, D | 1 |
| Schuster, E | 1 |
| Greene, ND | 1 |
| Gems, D | 1 |
| Moiseeva, O | 1 |
| Deschênes-Simard, X | 1 |
| Ferbeyre, G | 1 |
| Anisimov, VN | 7 |
| Na, HJ | 1 |
| Park, JS | 1 |
| Pyo, JH | 1 |
| Lee, SH | 1 |
| Jeon, HJ | 1 |
| Kim, YS | 1 |
| Yoo, MA | 1 |
| Mennes, E | 1 |
| Dungan, CM | 2 |
| Frendo-Cumbo, S | 1 |
| Williamson, DL | 2 |
| Wright, DC | 2 |
| Alagiakrishnan, K | 1 |
| Sankaralingam, S | 1 |
| Ghosh, M | 1 |
| Mereu, L | 1 |
| Senior, P | 1 |
| Ito, K | 1 |
| Mercado, N | 1 |
| Burkewitz, K | 1 |
| Mair, WB | 1 |
| Miles, JM | 1 |
| Rule, AD | 1 |
| Borlaug, BA | 1 |
| Fontana, L | 1 |
| Kennedy, BK | 1 |
| Longo, VD | 1 |
| Seals, D | 1 |
| Melov, S | 1 |
| Cetrone, M | 1 |
| Mele, A | 1 |
| Tricarico, D | 1 |
| Racaru-Honciuc, V | 1 |
| Betea, D | 1 |
| Scheen, AJ | 1 |
| Brown, S | 1 |
| Blagosklonny, MV | 5 |
| Popovich, IG | 3 |
| Zabezhinski, MA | 3 |
| Egormin, PA | 3 |
| Yurova, MN | 1 |
| Semenchenko, AV | 3 |
| Tyndyk, ML | 3 |
| Panchenko, AV | 1 |
| Trashkov, AP | 1 |
| Vasiliev, AG | 1 |
| Khaitsev, NV | 1 |
| de Kreutzenberg, SV | 1 |
| Ceolotto, G | 1 |
| Cattelan, A | 1 |
| Pagnin, E | 1 |
| Mazzucato, M | 1 |
| Garagnani, P | 1 |
| Borelli, V | 1 |
| Bacalini, MG | 1 |
| Franceschi, C | 1 |
| Fadini, GP | 1 |
| Avogaro, A | 1 |
| Check Hayden, E | 1 |
| Weintraub, K | 1 |
| Hall, SS | 1 |
| Allard, JS | 1 |
| Perez, EJ | 1 |
| Fukui, K | 1 |
| Carpenter, P | 1 |
| Ingram, DK | 2 |
| Daskalopoulos, EP | 1 |
| Dufeys, C | 1 |
| Bertrand, L | 1 |
| Beauloye, C | 1 |
| Horman, S | 1 |
| Mogul, H | 1 |
| Freeman, R | 1 |
| Nguyen, K | 1 |
| Novelle, MG | 1 |
| Ali, A | 1 |
| Diéguez, C | 2 |
| Bernier, M | 2 |
| Noren Hooten, N | 1 |
| Martin-Montalvo, A | 1 |
| Dluzen, DF | 1 |
| Zonderman, AB | 1 |
| Becker, KG | 1 |
| Gorospe, M | 1 |
| Evans, MK | 1 |
| Lee, YS | 1 |
| Doonan, BB | 1 |
| Wu, JM | 1 |
| Hsieh, TC | 1 |
| Wright, JJ | 1 |
| Tylee, TS | 1 |
| Schafer, MJ | 1 |
| LeBrasseur, NK | 1 |
| Magnussen, LV | 1 |
| Glintborg, D | 1 |
| Hermann, P | 1 |
| Hougaard, DM | 1 |
| Højlund, K | 1 |
| Andersen, M | 1 |
| López-Otín, C | 1 |
| Galluzzi, L | 1 |
| Freije, JMP | 1 |
| Newman, JC | 1 |
| Milman, S | 1 |
| Hashmi, SK | 1 |
| Austad, SN | 1 |
| Kirkland, JL | 1 |
| Halter, JB | 1 |
| Lankin, VZ | 1 |
| Tikhaze, AK | 1 |
| Gifford, B | 1 |
| Castillo-Quan, JI | 1 |
| Blackwell, TK | 1 |
| Zhou, B | 1 |
| Oshiro-Rapley, N | 1 |
| Li, M | 1 |
| Paulo, JA | 1 |
| Webster, CM | 1 |
| Mou, F | 1 |
| Kacergis, MC | 1 |
| Talkowski, ME | 1 |
| Carr, CE | 1 |
| Gygi, SP | 1 |
| Zheng, B | 1 |
| Gordon, J | 1 |
| McEwan, P | 1 |
| Evans, M | 1 |
| Puelles, J | 1 |
| Sinclair, A | 1 |
| Dong, D | 1 |
| Ning, YC | 1 |
| Wang, JC | 1 |
| Lv, Y | 1 |
| Hong, Q | 1 |
| Cui, SY | 1 |
| Fu, B | 1 |
| Guo, YN | 1 |
| Wang, CP | 1 |
| Lorenzo, C | 1 |
| Habib, SL | 1 |
| Jo, B | 1 |
| Campisi, J | 1 |
| Berstein, LM | 3 |
| Piskunova, TS | 2 |
| Yurova, MV | 2 |
| Kovalenko, IG | 2 |
| Poroshina, TE | 2 |
| González, CR | 1 |
| Caminos, JE | 1 |
| Vázquez, MJ | 1 |
| Garcés, MF | 1 |
| Cepeda, LA | 1 |
| Angel, A | 1 |
| González, AC | 1 |
| García-Rendueles, ME | 1 |
| Sangiao-Alvarellos, S | 1 |
| López, M | 1 |
| Bravo, SB | 1 |
| Nogueiras, R | 1 |
| Tzvetkov, MV | 1 |
| Vormfelde, SV | 1 |
| Balen, D | 1 |
| Meineke, I | 1 |
| Schmidt, T | 1 |
| Sehrt, D | 1 |
| Sabolić, I | 1 |
| Koepsell, H | 1 |
| Brockmöller, J | 1 |
| Turdi, S | 1 |
| Fan, X | 1 |
| Zhao, J | 1 |
| Huff, AF | 1 |
| Du, M | 1 |
| Ren, J | 1 |
| Sharp, ZD | 1 |
| Rosenfeld, SV | 1 |
| Cufí, S | 1 |
| Oliveras-Ferraros, C | 1 |
| Vellon, L | 1 |
| Vazquez-Martin, A | 1 |
| Bulterijs, S | 1 |
| Kaneb, HM | 1 |
| Sharp, PS | 1 |
| Rahmani-Kondori, N | 1 |
| Wells, DJ | 1 |
| Lee, CG | 1 |
| Boyko, EJ | 1 |
| Barrett-Connor, E | 1 |
| Miljkovic, I | 1 |
| Hoffman, AR | 1 |
| Everson-Rose, SA | 1 |
| Lewis, CE | 1 |
| Cawthon, PM | 1 |
| Strotmeyer, ES | 1 |
| Orwoll, ES | 1 |
| Potts, MB | 1 |
| Lim, DA | 1 |
| Gallagher, D | 1 |
| DeVito, LM | 1 |
| Cancino, GI | 1 |
| Tsui, D | 1 |
| He, L | 1 |
| Keller, GM | 1 |
| Frankland, PW | 1 |
| Kaplan, DR | 1 |
| Miller, FD | 1 |
| Whittington, HJ | 1 |
| Hall, AR | 1 |
| McLaughlin, CP | 1 |
| Hausenloy, DJ | 1 |
| Yellon, DM | 1 |
| Mocanu, MM | 1 |
| Montagnani, A | 1 |
| Gonnelli, S | 1 |
| McCarty, MF | 1 |
| Lenhard, JM | 1 |
| Croom, DK | 1 |
| Minnick, DT | 1 |
| Piltonen, T | 1 |
| Morin-Papunen, L | 1 |
| Koivunen, R | 1 |
| Perheentupa, A | 1 |
| Ruokonen, A | 1 |
| Tapanainen, JS | 1 |
| Holstein, A | 1 |
| Stumvoll, M | 1 |
| Spinney, L | 1 |
| Reddy, VP | 1 |
| Beyaz, A | 1 |
| de Zegher, F | 1 |
| Ibáñez, L | 1 |
| Alemzadeh, R | 1 |
| Ellis, J | 1 |
| Calhoun, M | 1 |
| Kichler, J | 1 |
| Benko, A | 1 |
| Fraser-Hill, M | 1 |
| Magner, P | 1 |
| Capusten, B | 1 |
| Barrett, B | 1 |
| Myers, A | 1 |
| Owen, RJ | 1 |
| Verma, S | 1 |
| Bhanot, S | 1 |
| McNeill, JH | 1 |
| Gregorio, F | 2 |
| Ambrosi, F | 2 |
| Filipponi, P | 2 |
| Manfrini, S | 2 |
| Testa, I | 1 |
| Kosegawa, I | 1 |
| Katayama, S | 1 |
| Kikuchi, C | 1 |
| Kashiwabara, H | 1 |
| Negishi, K | 1 |
| Ishii, J | 1 |
| Inukai, K | 1 |
| Oka, Y | 1 |
| Mori, K | 1 |
| Nakamura, J | 1 |
| Koh, N | 1 |
| Sakakibara, F | 1 |
| Hamada, Y | 1 |
| Hara, T | 1 |
| Komori, T | 1 |
| Nakashima, E | 1 |
| Naruse, K | 1 |
| Takeuchi, N | 1 |
| Hotta, N | 1 |
| Beales, PE | 1 |
| Giorgini, A | 1 |
| Annovazzi, A | 1 |
| Signore, A | 1 |
| Parlapiano, C | 1 |
| Pozzilli, P | 1 |
| Velussi, M | 1 |
| Carle, F | 1 |
| Testa, R | 1 |
| Merante, D | 1 |
| Chan, NN | 1 |
| Feher, MD | 1 |
| Borst, SE | 1 |
| Snellen, HG | 1 |
| Roth, GS | 1 |
| Lane, MA | 1 |
| Junien, JL | 1 |
| Brohon, J | 1 |
| Guillaume, M | 1 |
| Sterne, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Obesity-related Mechanisms and Mortality in Breast Cancer Survivors[NCT01302379] | 333 participants (Actual) | Interventional | 2011-08-31 | Completed | |||
| Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients[NCT05298670] | Phase 2 | 80 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | ||
| Anti-Inflammatory, Insulin-Sensitizing Agent for Treatment of Cognitive Decline Due to Degenerative Dementias[NCT05227820] | Phase 2 | 23 participants (Actual) | Interventional | 2022-01-19 | Completed | ||
| Novel Actions of Metformin to Augment Resistance Training Adaptations in Older Adults[NCT02308228] | Early Phase 1 | 109 participants (Actual) | Interventional | 2015-01-14 | Completed | ||
| Randomized Clinical Trial to Evaluate The Effect of Metformin-GLP-1 Receptor Agonist Versus Oral Contraceptive (OC) Therapy on Reproductive Disorders and Cardiovascular Risks in Overweight Polycystic Ovarian Syndrome (PCOS) Patients[NCT03151005] | Phase 4 | 70 participants (Actual) | Interventional | 2017-07-01 | Completed | ||
| A Small-Scale Study to Explore the Safety and Feasibility of Allogeneic Young Plasma Infusion in Older Adults Experiencing Disability Across the Spectrum of Frailty Syndrome[NCT04241159] | Early Phase 1 | 0 participants (Actual) | Interventional | 2020-05-31 | Withdrawn (stopped due to Protocol required revisions and application was withdrawn from the IRB.) | ||
| Fasting to Provide Energy Needed to Help Adults in Need of Cognitive Enhancement (FASTING ENHANCE)[NCT05732935] | 52 participants (Anticipated) | Interventional | 2023-03-13 | Recruiting | |||
| The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes[NCT05284344] | 100 participants (Anticipated) | Observational | 2021-01-24 | Active, not recruiting | |||
| The Role of Sirolimus in Preventing Functional Decline in Older Adults[NCT05237687] | Phase 2 | 14 participants (Anticipated) | Interventional | 2024-03-31 | Not yet recruiting | ||
| "Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Metformin, an Activator of AMPK, on Cognitive Measures of Progression in Huntington's Disease Patients"[NCT04826692] | Phase 3 | 60 participants (Anticipated) | Interventional | 2021-12-10 | Recruiting | ||
| Effects of Metformin on Longevity Gene Expression and Inflammation and Prediabetic Individuals. A Placebo-controlled Trial[NCT01765946] | Phase 4 | 38 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| EMPOWIR: Enhance the Metabolic Profile of Women With Insulin Resistance: Carbohydrate Modified Diet Alone and in Combination With Metformin or Metformin Plus Avandia in Non-diabetic Women With Midlife Weight Gain and Documented Insulin Elevations (Syndrom[NCT00618072] | Phase 2 | 46 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| The Efficacy And Safety Of Metformin For The Treatment Of Atrial Fibrillation[NCT05878535] | Phase 4 | 770 participants (Anticipated) | Interventional | 2023-06-01 | Not yet recruiting | ||
| Prospective, Double Blind, Randomized Trial: Meniscal Repair With or Without Augmentation Utilizing Platelet Rich Plasma.[NCT01991353] | 0 participants (Actual) | Interventional | 2015-07-31 | Withdrawn (stopped due to Lack of funding) | |||
| The Prevention Contrast-Induced Acute Kidney Injury With the Triple Combination of Hydration With Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate[NCT01210456] | Phase 3 | 458 participants (Anticipated) | Interventional | 2009-10-31 | Enrolling by invitation | ||
| Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes[NCT04943692] | Phase 3 | 500 participants (Anticipated) | Interventional | 2021-08-31 | Suspended (stopped due to Administrative decision of the investigation direction) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Bioavailable testosterone measured as percent change from baseline (NCT01302379)
Timeframe: change from baseline to 6 months
| Intervention | percent change from baseline (Least Squares Mean) |
|---|---|
| Metformin + Lifestyle Intervention | -13.7 |
| Placebo + Lifestyle Intervention | -4.5 |
| Metformin + Standard Dietary Guidelines | -11.1 |
| Placebo + Standard Dietary Guidelines | -1.3 |
C-reactive protein measured as percent change from baseline (NCT01302379)
Timeframe: change from baseline to 6 months
| Intervention | percent change from baseline (Least Squares Mean) |
|---|---|
| Metformin + Lifestyle Intervention | -21.4 |
| Placebo + Lifestyle Intervention | -6.7 |
| Metformin + Standard Dietary Guidelines | -9.2 |
| Placebo + Standard Dietary Guidelines | 5.9 |
Glucose measured as percent change from baseline (NCT01302379)
Timeframe: change from baseline to 6 months
| Intervention | percent change from baseline (Least Squares Mean) |
|---|---|
| Metformin + Lifestyle Intervention | -1.2 |
| Placebo + Lifestyle Intervention | -2.3 |
| Metformin + Standard Dietary Guidelines | -1.6 |
| Placebo + Standard Dietary Guidelines | 2.0 |
Insulin measured as percent change from baseline (NCT01302379)
Timeframe: change from baseline to 6 months
| Intervention | percent change from baseline (Least Squares Mean) |
|---|---|
| Metformin + Lifestyle Intervention | -21.8 |
| Placebo + Lifestyle Intervention | -17.7 |
| Metformin + Standard Dietary Guidelines | -13.2 |
| Placebo + Standard Dietary Guidelines | -1.1 |
Serum hormone binding globulin measured as percent change from baseline (NCT01302379)
Timeframe: change from baseline to 6 months
| Intervention | percent change from baseline (Least Squares Mean) |
|---|---|
| Metformin + Lifestyle Intervention | 12.5 |
| Placebo + Lifestyle Intervention | 7.6 |
| Metformin + Standard Dietary Guidelines | 9.8 |
| Placebo + Standard Dietary Guidelines | -0.1 |
Determine if metformin treatment augments strength gains in conjunction with progressive resistance training by one repetition maximum assessments. Maximum (1RM) leg extension muscle strength was assessed at week 4 (to account for neurological adaptations during the initial stages of the resistance program) and week 16. The percent change from week 4 to week 16 is reported. (NCT02308228)
Timeframe: Week 4 and week 16
| Intervention | Percent change (Mean) |
|---|---|
| Metformin | 15.3 |
| Placebo, Sugar Pill | 23.1 |
The ability of metformin to improve the hypertrophic response at the whole muscle level will be quantified by computed tomography. Percent change in normal density muscle area will be calculated as the difference between week 16 and week 0. (NCT02308228)
Timeframe: 16 weeks
| Intervention | Percent change (Mean) |
|---|---|
| Metformin | 4.2 |
| Placebo, Sugar Pill | 10.5 |
To determine if metformin improves changes in body composition associated with progressive resistance training. Percent change in total body lean mass in kg was calculated as the difference between week 16 and week 0 from a total body DXA scan. (NCT02308228)
Timeframe: 16 weeks
| Intervention | Percent change (Mean) |
|---|---|
| Metformin | 0.41 |
| Placebo, Sugar Pill | 1.95 |
The ability of metformin to improve the hypertrophic response to resistance training will be determined. Muscle biopsies of the vastus lateralis will be used to quantify myofiber cross-sectional area. The percent change in type 2 myofiber size between week 16 and week 0 was used. (NCT02308228)
Timeframe: 16 weeks
| Intervention | Percent change (Mean) |
|---|---|
| Metformin | 18.5 |
| Placebo, Sugar Pill | 14.5 |
Systolic blood pressure was measured in mmHg. (NCT03151005)
Timeframe: 12 weeks
| Intervention | mmHg (Mean) |
|---|---|
| Metformin-GLP-1 Receptor Agonist | 122.83 |
| Metformin-Oral Contraceptive(OC) | 122.40 |
Alanine transaminase was measured in IU/L. (NCT03151005)
Timeframe: 12 weeks
| Intervention | IU/L (Mean) |
|---|---|
| Metformin-GLP-1 Receptor Agonist | 39.09 |
| Metformin-Oral Contraceptive(OC) | 36.73 |
Changes in testosterone levels were measured (NCT03151005)
Timeframe: 12 weeks
| Intervention | nmol/L (Mean) |
|---|---|
| Metformin-GLP-1 Receptor Agonist | 1.82 |
| Metformin-Oral Contraceptive(OC) | 2.14 |
Concentration of LH was measured in mIU/ml. (NCT03151005)
Timeframe: 12 weeks
| Intervention | mIU/ml (Mean) |
|---|---|
| Metformin-GLP-1 Receptor Agonist | 5.52 |
| Metformin-Oral Contraceptive(OC) | 5.33 |
Weight and height will be combined to report BMI in kg/m^2. (NCT03151005)
Timeframe: 12 weeks
| Intervention | kg/m^2 (Mean) |
|---|---|
| Metformin-GLP-1 Receptor Agonist | 26.26 |
| Metformin-Oral Contraceptive(OC) | 27.12 |
Total adiponectin was measured with a commercial ELISA kit (Millipore/Linco Research, St. Charles, MO) in the laboratory of Dr. Philipp Scherer. (NCT00618072)
Timeframe: 6 months
| Intervention | ug/mL (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 10.6 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 10.9 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 18.5 |
Body weight measurement was performed three times and averaged by a single study coordinator. (NCT00618072)
Timeframe: 6 months
| Intervention | kg (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 80.0 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 80.4 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 77.5 |
Blood pressure was assessed using NCEP guidelines. (NCT00618072)
Timeframe: 6 months
| Intervention | mmHg (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 71.7 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 72.7 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 74.3 |
Insulin was determined with a Siemens Immulite assay with respective intra-and inter-CV's 5.7 and 5.9%, and no cross reactivity to pro-insulin. (NCT00618072)
Timeframe: 6 months
| Intervention | uIU/mL (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 8.1 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 8.0 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 6.3 |
HDL was measured using two reagents homogeneous systems with selective detergents to homogenize the lipoprotein of interest. (NCT00618072)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 56.5 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 70.1 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 68.3 |
HOMA-IR was calculated by the formula: fasting insulin (uU/mL) times fasting glucose (mg/L) divided by 22.5. (NCT00618072)
Timeframe: 6 months
| Intervention | HOMA-IR score (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 1.5 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 1.6 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 1.3 |
Blood pressure was assessed using NCEP guidelines. (NCT00618072)
Timeframe: 6 months
| Intervention | mmHg (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 113.8 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 107.2 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 114.2 |
Triglycerides were measured by enzymatic immunoassay on an AU400 chemistry auto-analyzer with commercially available enzymatic reagents. (NCT00618072)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 95.2 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 103.1 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 109.2 |
(NCT00618072)
Timeframe: 6 months
| Intervention | cm (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 93.1 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 90.4 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 87.5 |
69 reviews available for metformin and Aging
| Article | Year |
|---|---|
New Insight into the Effects of Metformin on Diabetic Retinopathy, Aging and Cancer: Nonapoptotic Cell Death, Immunosuppression, and Effects beyond the AMPK Pathway.
Topics: Aging; AMP-Activated Protein Kinases; Blood Glucose; Cell Death; Diabetes Mellitus, Type 2; Diabetic | 2021 |
Possible Involvement of Adipose Tissue in Patients With Older Age, Obesity, and Diabetes With SARS-CoV-2 Infection (COVID-19) via GRP78 (BIP/HSPA5): Significance of Hyperinsulinemia Management in COVID-19.
Topics: Adipose Tissue; Adrenergic beta-3 Receptor Agonists; Aged; Aging; Angiotensin-Converting Enzyme 2; A | 2021 |
Pharmacy and Exercise as Complimentary Partners for Successful Cardiovascular Ageing.
Topics: Adrenergic beta-Antagonists; Aged; Aging; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular D | 2022 |
[A multidirectional effect of metformin].
Topics: Aging; Animals; Diabetes Mellitus; Female; Hypoglycemic Agents; Metformin; Neoplasms | 2022 |
Metformin in aging and aging-related diseases: clinical applications and relevant mechanisms.
Topics: Aging; Cellular Senescence; Genomic Instability; Humans; Metformin; Telomere | 2022 |
Type 2 diabetes mellitus accelerates brain aging and cognitive decline: Complementary findings from UK Biobank and meta-analyses.
Topics: Aged; Aged, 80 and over; Aging; Atrophy; Biological Specimen Banks; Cognitive Dysfunction; Cross-Sec | 2022 |
Repurposing Metformin for Vascular Disease.
Topics: Aging; Animals; COVID-19; Drug Repositioning; Endothelial Cells; Exercise; Humans; Metformin; Vascul | 2023 |
[Cardiovascular prevention in old age-Cardiovascular prevention of ageing?]
Topics: Adult; Aged; Aging; Cardiovascular Diseases; Cardiovascular System; Fibrinolytic Agents; Humans; Lip | 2022 |
Importance of Bmal1 in Alzheimer's disease and associated aging-related diseases: Mechanisms and interventions.
Topics: Adiponectin; Aging; Alzheimer Disease; ARNTL Transcription Factors; Diabetes Mellitus, Type 2; Human | 2022 |
A blast from the past: To tame time with metformin.
Topics: Aging; Animals; Diabetes Mellitus, Type 2; Geriatrics; Humans; Hypoglycemic Agents; Longevity; Metfo | 2022 |
Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans: A systematic review and meta-analysis.
Topics: Aging; Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Humans; Longevity; Metformi | 2022 |
Effects of lifespan-extending interventions on cognitive healthspan.
Topics: Aging; Animals; Caloric Restriction; Cognition; Longevity; Metformin | 2022 |
Anti-ageing effects of FDA-approved medicines: a focused review.
Topics: Acarbose; Aging; Animals; Canagliflozin; Longevity; Male; Metformin; Quality of Life | 2023 |
Mechanisms of ageing: growth hormone, dietary restriction, and metformin.
Topics: Aging; Animals; Growth Hormone; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Metformi | 2023 |
The function, mechanisms, and clinical applications of metformin: potential drug, unlimited potentials.
Topics: Aging; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms | 2023 |
The development and benefits of metformin in various diseases.
Topics: Aging; AMP-Activated Protein Kinases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metfor | 2023 |
Metformin as Anti-Aging Therapy: Is It for Everyone?
Topics: Aging; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lysosomes; Metformin; Mitochondria; P | 2019 |
Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, P | 2019 |
Metformin and Aging: A Review.
Topics: Aging; AMP-Activated Protein Kinase Kinases; Animals; Cellular Senescence; Clinical Trials as Topic; | 2019 |
The Use of Metformin to Increase the Human Healthspan.
Topics: Aged; Aging; Clinical Trials as Topic; Disease; Frailty; Humans; Longevity; Metformin | 2020 |
Benefits of Metformin in Attenuating the Hallmarks of Aging.
Topics: Aging; Animals; Autophagy; Cell Communication; Cellular Senescence; Humans; Hypoglycemic Agents; Met | 2020 |
Metformin and Its Benefits for Various Diseases.
Topics: Aging; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Signal | 2020 |
Is metformin a geroprotector? A peek into the current clinical and experimental data.
Topics: Aging; Animals; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Metformin; Neoplasms | 2020 |
Targeting ageing and preventing organ degeneration with metformin.
Topics: Aging; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin | 2021 |
T helper 17 cells: A new actor on the stage of type 2 diabetes and aging?
Topics: Aging; Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metformi | 2021 |
Repurposing metformin to treat age-related neurodegenerative disorders and ischemic stroke.
Topics: Aging; Animals; Brain Ischemia; Drug Repositioning; Humans; Hypoglycemic Agents; Metformin; Neurodeg | 2021 |
The Role of Mitochondria in Immune-Cell-Mediated Tissue Regeneration and Ageing.
Topics: Adaptive Immunity; Aging; Animals; Antigen-Presenting Cells; B-Lymphocyte Subsets; Cytokines; DNA; D | 2021 |
Investigational drugs and nutrients for human longevity. Recent clinical trials registered in ClinicalTrials.gov and clinicaltrialsregister.eu.
Topics: Acarbose; Aging; Animals; Drugs, Investigational; Humans; Longevity; Metformin; Nutrients; Sirolimus | 2021 |
A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan.
Topics: Aging; Animals; Caenorhabditis elegans; Diabetes Mellitus, Type 2; Humans; Longevity; Metformin; Mic | 2021 |
Molecular and physiological manifestations and measurement of aging in humans.
Topics: Aging; Biomarkers; Cellular Senescence; Cytokines; Epigenesis, Genetic; Gene-Environment Interaction | 2017 |
THE ENDOCRINOLOGY OF AGING: A KEY TO LONGEVITY "GREAT EXPECTATIONS".
Topics: Aging; Animals; Antioxidants; Endocrine Glands; Glucuronidase; Humans; Klotho Proteins; Longevity; M | 2017 |
Metformin and ageing: improving ageing outcomes beyond glycaemic control.
Topics: Aging; Animals; Blood Glucose; Humans; Hypoglycemic Agents; Metformin | 2017 |
Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis.
Topics: Aging; Cardiovascular Diseases; Case-Control Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemi | 2017 |
Metformin: a review of its potential indications.
Topics: Aging; Antineoplastic Agents; Blood Glucose; Cardiotonic Agents; Diabetes Mellitus, Type 2; Female; | 2017 |
Geroprotectors as a therapeutic strategy for COPD - where are we now?
Topics: Aging; Disease Progression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Me | 2017 |
[In process].
Topics: Aged; Aging; Animals; Chronic Disease; Humans; Hypoglycemic Agents; Metformin; Risk Factors | 2016 |
A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup.
Topics: Aging; Biomarkers; Biomedical Research; Humans; Hypoglycemic Agents; Metformin; Randomized Controlle | 2018 |
A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup.
Topics: Aging; Biomarkers; Biomedical Research; Humans; Hypoglycemic Agents; Metformin; Randomized Controlle | 2018 |
A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup.
Topics: Aging; Biomarkers; Biomedical Research; Humans; Hypoglycemic Agents; Metformin; Randomized Controlle | 2018 |
A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup.
Topics: Aging; Biomarkers; Biomedical Research; Humans; Hypoglycemic Agents; Metformin; Randomized Controlle | 2018 |
Metformin as a geroprotector: experimental and clinical evidence.
Topics: Aging; Humans; Hypoglycemic Agents; Longevity; Metformin; Protective Agents | 2019 |
Pleiotropic effects of metformin: Shaping the microbiome to manage type 2 diabetes and postpone ageing.
Topics: Aging; Animals; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Managemen | 2018 |
Autophagy in Cardiovascular Aging.
Topics: Age Factors; Aging; Animals; Autophagy; Caloric Restriction; Cardiovascular Diseases; Cardiovascular | 2018 |
Energy restriction in renal protection.
Topics: Aging; Animals; Autophagy; Caloric Restriction; Diet; Energy Metabolism; Female; Humans; Inflammatio | 2018 |
Prospects of Pharmacological Interventions to Organismal Aging.
Topics: Aging; Animals; Aspirin; Growth Hormone; Humans; Metformin; Resveratrol; Signal Transduction; TOR Se | 2018 |
Taming expectations of metformin as a treatment to extend healthspan.
Topics: Aged; Aged, 80 and over; Aging; Female; Geriatrics; Humans; Hypoglycemic Agents; Longevity; Male; Me | 2019 |
NF-κB as the mediator of metformin's effect on ageing and ageing-related diseases.
Topics: Aging; Animals; Disease; Humans; Metformin; Molecular Targeted Therapy; NF-kappa B | 2019 |
Metformin: Mechanisms in Human Obesity and Weight Loss.
Topics: Aging; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Gastrointestinal Microbiome; Huma | 2019 |
Rapalogs and mTOR inhibitors as anti-aging therapeutics.
Topics: Aging; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Autophagy; Humans; Metformin; Molec | 2013 |
Metformin: do we finally have an anti-aging drug?
Topics: Aging; Animals; Carcinogenesis; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin | 2013 |
Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Animals; Clinical Trials as Topic; Cognition Diso | 2013 |
STOP accelerating lung aging for the treatment of COPD.
Topics: Aging; Disease Progression; Humans; Inflammation; Lung; Metformin; Oxidative Stress; Pulmonary Disea | 2014 |
AMPK at the nexus of energetics and aging.
Topics: Aging; AMP-Activated Protein Kinases; Animals; Aspirin; Energy Metabolism; Humans; Metabolic Disease | 2014 |
Use of metformin in diseases of aging.
Topics: Aging; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Administratio | 2014 |
Effects of the antidiabetic drugs on the age-related atrophy and sarcopenia associated with diabetes type II.
Topics: Age Factors; Aging; AMP-Activated Protein Kinases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic A | 2014 |
Koschei the immortal and anti-aging drugs.
Topics: Aging; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Caloric Restriction; Exercise; Folklore; G | 2014 |
AMPK in cardiac fibrosis and repair: Actions beyond metabolic regulation.
Topics: Aging; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Berberine; Cardiomegaly; Extracell | 2016 |
Metformin: A Hopeful Promise in Aging Research.
Topics: Aging; Humans; Life Expectancy; Metformin; Translational Research, Biomedical | 2016 |
Pharmacologic Therapy of Type 2 Diabetes.
Topics: Aging; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dr | 2016 |
Energetic interventions for healthspan and resiliency with aging.
Topics: Aging; Caloric Restriction; Diet; Energy Intake; Exercise; Female; Humans; Longevity; Male; Metformi | 2016 |
Metformin as a Tool to Target Aging.
Topics: Aging; Animals; Clinical Trials as Topic; Humans; Longevity; Metformin; Models, Animal; Models, Biol | 2016 |
Metabolic Control of Longevity.
Topics: Aging; Animals; Caloric Restriction; Cellular Senescence; Diet; Diet, Western; Exercise; Humans; Lif | 2016 |
Role of Oxidative Stress in the Genesis of Atherosclerosis and Diabetes Mellitus: A Personal Look Back on 50 Years of Research.
Topics: Aging; Animals; Antioxidants; Atherosclerosis; Diabetes Mellitus; Free Radicals; Glucose; Humans; Hy | 2017 |
Validation of anti-aging drugs by treating age-related diseases.
Topics: Aging; Animals; Antibiotics, Antineoplastic; Antioxidants; Biomarkers; Chronic Disease; Humans; Hypo | 2009 |
Aging and TOR: interwoven in the fabric of life.
Topics: Aging; Animals; Anti-Infective Agents; Humans; Hypoglycemic Agents; Metformin; Sirolimus; TOR Serine | 2011 |
Metformin for aging and cancer prevention.
Topics: Aging; Animals; Antineoplastic Agents; Biguanides; Caloric Restriction; Humans; Hyperglycemia; Hypog | 2010 |
Metformin as a geroprotector.
Topics: Aging; Animals; Caloric Restriction; Geriatrics; Humans; Longevity; Metformin | 2011 |
Metformin in obesity, cancer and aging: addressing controversies.
Topics: Aging; Animals; Body Weight; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metform | 2012 |
Antidiabetic therapy effects on bone metabolism and fracture risk.
Topics: Aging; Animals; Bone Density; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Pepti | 2013 |
Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases.
Topics: Aging; Animals; Diabetes Mellitus, Type 2; Glycation End Products, Advanced; Guanidines; Humans; Hyp | 2006 |
An anti-aging drug today: from senescence-promoting genes to anti-aging pill.
Topics: Aging; Animals; Antioxidants; Caloric Restriction; Cell Cycle Proteins; Cellular Senescence; Drug De | 2007 |
Caloric restriction in primates and relevance to humans.
Topics: Aging; Animals; Biomarkers; Blood Glucose; Body Temperature; Cardiovascular Diseases; Deoxyglucose; | 2001 |
8 trials available for metformin and Aging
| Article | Year |
|---|---|
Antecedent Metabolic Health and Metformin (ANTHEM) Aging Study: Rationale and Study Design for a Randomized Controlled Trial.
Topics: Aged; Aging; Double-Blind Method; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformi | 2022 |
Metformin to Augment Strength Training Effective Response in Seniors (MASTERS): study protocol for a randomized controlled trial.
Topics: Age Factors; Aged; Aging; Alabama; Clinical Protocols; Double-Blind Method; Female; Geriatric Assess | 2017 |
Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes: A randomized, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Aging; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase | 2018 |
Metformin improves putative longevity effectors in peripheral mononuclear cells from subjects with prediabetes. A randomized controlled trial.
Topics: Aging; AMP-Activated Protein Kinases; Biomarkers; Blood Glucose; Cell Death; Female; Humans; Hypogly | 2015 |
METFORMIN-SUSTAINED WEIGHT LOSS AND REDUCED ANDROID FAT TISSUE AT 12 MONTHS IN EMPOWIR (ENHANCE THE METABOLIC PROFILE OF WOMEN WITH INSULIN RESISTANCE): A DOUBLE BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF NORMOGLYCEMIC WOMEN WITH MIDLIFE WEIGHT GAIN.
Topics: Adipose Tissue; Adult; Aging; Body Fat Distribution; Climacteric; Double-Blind Method; Drug Combinat | 2016 |
Effect of testosterone on insulin sensitivity, oxidative metabolism and body composition in aging men with type 2 diabetes on metformin monotherapy.
Topics: Adult; Aged; Aging; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Double-Blind Method; | 2016 |
Is metformin safe enough for ageing type 2 diabetic patients?
Topics: Aged; Aged, 80 and over; Aging; Anthropometry; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therap | 1996 |
Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin.
Topics: Aged; Aging; Antithrombin III; Blood Glucose; Blood Platelets; Cholesterol, HDL; Cholesterol, LDL; D | 1999 |
129 other studies available for metformin and Aging
| Article | Year |
|---|---|
Impact of overlapping risks of type 2 diabetes and obesity on coronavirus disease severity in the United States.
Topics: Aged; Aging; COVID-19; COVID-19 Drug Treatment; Critical Care; Diabetes Complications; Diabetes Mell | 2021 |
A high fat, sugar, and salt Western diet induces motor-muscular and sensory dysfunctions and neurodegeneration in mice during aging: Ameliorative action of metformin.
Topics: Aged; Aging; Animals; Diet, Carbohydrate Loading; Diet, High-Fat; Diet, Western; Disease Models, Ani | 2021 |
[Metformin and ageing: can treatment delay age-related diseases?]
Topics: Aging; Exercise; Humans; Hypoglycemic Agents; Life Style; Metformin; Time-to-Treatment | 2021 |
Metformin alleviates stress-induced cellular senescence of aging human adipose stromal cells and the ensuing adipocyte dysfunction.
Topics: Adipocytes; Aging; AMP-Activated Protein Kinases; Cells, Cultured; Cellular Senescence; Female; Huma | 2021 |
Metformin Protects Against Inflammation, Oxidative Stress to Delay Poly I:C-Induced Aging-Like Phenomena in the Gut of an Annual Fish.
Topics: Aging; AMP-Activated Protein Kinases; Animals; Cytokines; Diabetes Mellitus, Type 2; Female; Inflamm | 2022 |
Metformin reduces ageing adipose senescence.
Topics: Adipose Tissue; Aging; Humans; Hypoglycemic Agents; Metformin | 2021 |
Elucidating Carfilzomib's Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin.
Topics: Aging; AMP-Activated Protein Kinases; Animals; Autophagy; Heart; Leukocytes, Mononuclear; Male; Metf | 2021 |
Metformin Treatment in Old Rats and Effects on Mitochondrial Integrity.
Topics: Aging; Animals; Diabetes Mellitus, Type 2; DNA, Mitochondrial; Metformin; Mitochondria; Rats | 2021 |
Metformin treatment of juvenile mice alters aging-related developmental and metabolic phenotypes.
Topics: Adiponectin; Age Factors; Aging; Animals; Body Weight; Feeding Behavior; Glucose Tolerance Test; Gro | 2022 |
Metformin treatment of diverse Caenorhabditis species reveals the importance of genetic background in longevity and healthspan extension outcomes.
Topics: Aging; Animals; Caenorhabditis elegans; Humans; Hypoglycemic Agents; Longevity; Metformin; Treatment | 2022 |
An epigenetic aging analysis of randomized metformin and weight loss interventions in overweight postmenopausal breast cancer survivors.
Topics: Aged; Aging; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Metformin; Middle Aged; Overweight | 2021 |
Metformin alleviates the depression-like behaviors of elderly apoE4 mice via improving glucose metabolism and mitochondrial biogenesis.
Topics: Aging; Animals; Apolipoprotein E3; Apolipoprotein E4; Behavior, Animal; Depression; Disease Models, | 2022 |
Metformin attenuated sepsis-associated liver injury and inflammatory response in aged mice.
Topics: Aging; Animals; Inflammation; Lipopolysaccharides; Liver; Liver Diseases; Male; Metformin; Mice; Mic | 2022 |
Effects of metformin on the uterus of d-galactose-induced aging mice: Histomorphometric, immunohistochemical localization (B-cell lymphoma 2, Bcl2-associated X protein, and active capase3), and oxidative stress study.
Topics: Aging; Animals; bcl-2-Associated X Protein; Caspase 3; Female; Galactose; Metformin; Mice; Oxidative | 2022 |
Metformin ameliorates thymus degeneration of mice by regulating mitochondrial function.
Topics: Aging; Animals; Cellular Senescence; Galactose; Metformin; Mice; Mitochondria; Thymus Gland | 2022 |
Metformin alleviates neurocognitive impairment in aging via activation of AMPK/BDNF/PI3K pathway.
Topics: Aging; AMP-Activated Protein Kinases; Animals; Brain-Derived Neurotrophic Factor; Caspase 3; Galacto | 2022 |
Metformin improves tendon degeneration by blocking translocation of HMGB1 and suppressing tendon inflammation and senescence in aging mice.
Topics: Aging; Animals; Cellular Senescence; HMGB1 Protein; Inflammation; Metformin; Mice; Tendons | 2023 |
Metformin suppresses progression of muscle aging via activation of the AMP kinase-mediated pathways in Drosophila adults.
Topics: Adenylate Kinase; Aging; AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Drosophi | 2022 |
Metformin suppresses progression of muscle aging via activation of the AMP kinase-mediated pathways in Drosophila adults.
Topics: Adenylate Kinase; Aging; AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Drosophi | 2022 |
Metformin suppresses progression of muscle aging via activation of the AMP kinase-mediated pathways in Drosophila adults.
Topics: Adenylate Kinase; Aging; AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Drosophi | 2022 |
Metformin suppresses progression of muscle aging via activation of the AMP kinase-mediated pathways in Drosophila adults.
Topics: Adenylate Kinase; Aging; AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Drosophi | 2022 |
Metformin suppresses progression of muscle aging via activation of the AMP kinase-mediated pathways in Drosophila adults.
Topics: Adenylate Kinase; Aging; AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Drosophi | 2022 |
Metformin suppresses progression of muscle aging via activation of the AMP kinase-mediated pathways in Drosophila adults.
Topics: Adenylate Kinase; Aging; AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Drosophi | 2022 |
Metformin suppresses progression of muscle aging via activation of the AMP kinase-mediated pathways in Drosophila adults.
Topics: Adenylate Kinase; Aging; AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Drosophi | 2022 |
Metformin suppresses progression of muscle aging via activation of the AMP kinase-mediated pathways in Drosophila adults.
Topics: Adenylate Kinase; Aging; AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Drosophi | 2022 |
Metformin suppresses progression of muscle aging via activation of the AMP kinase-mediated pathways in Drosophila adults.
Topics: Adenylate Kinase; Aging; AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Drosophi | 2022 |
Metformin use history and genome-wide DNA methylation profile: potential molecular mechanism for aging and longevity.
Topics: Aging; DNA; DNA Methylation; Epigenesis, Genetic; Humans; Longevity; Metformin | 2023 |
Intestinal stem cell aging at single-cell resolution: Transcriptional perturbations alter cell developmental trajectory reversed by gerotherapeutics.
Topics: Aging; Animals; Cellular Senescence; Intestinal Mucosa; Intestines; Metformin; Mice; Receptors, G-Pr | 2023 |
The Regulation of the AMPK/mTOR Axis Mitigates Tendon Stem/Progenitor Cell Senescence and Delays Tendon Aging.
Topics: Aging; AMP-Activated Protein Kinases; Animals; Cellular Senescence; Metformin; Rats; Stem Cells; Ten | 2023 |
Polyoxidovanadates as a pharmacological option against brain aging.
Topics: Aging; Animals; Antioxidants; Brain; Metformin; Oxidative Stress; Rats | 2023 |
Drugs Targeting Mechanisms of Aging to Delay Age-Related Disease and Promote Healthspan: Proceedings of a National Institute on Aging Workshop.
Topics: Aging; Humans; Metformin; NAD; National Institute on Aging (U.S.); Senotherapeutics; United States | 2023 |
A combination of metformin and galantamine exhibits synergistic benefits in the treatment of sarcopenia.
Topics: Aged; Aging; Animals; Galantamine; Humans; Infant; Metformin; Mice; Mice, Transgenic; Muscle, Skelet | 2023 |
mTORC1 inhibition may improve T lymphocytes affected by aging.
Topics: Aged; Aging; Animals; Everolimus; Humans; Interleukin-2; Mechanistic Target of Rapamycin Complex 1; | 2023 |
Metformin Restores CNS Remyelination Capacity by Rejuvenating Aged Stem Cells.
Topics: Aging; Animals; Cell Differentiation; Cells, Cultured; Central Nervous System; DNA Damage; Female; H | 2019 |
TAME: A Genuinely Good Use of 75 Million Dollars.
Topics: Aging; Clinical Protocols; Controlled Clinical Trials as Topic; Fund Raising; Humans; Hypoglycemic A | 2019 |
Age-related hyperinsulinemia leads to insulin resistance in neurons and cell-cycle-induced senescence.
Topics: Aging; Animals; beta Catenin; Cell Cycle; Cell Death; Cellular Senescence; Cyclin-Dependent Kinase 5 | 2019 |
[Interventional effects of metformin on senescence induced by D-galactose in middle-aged male mice].
Topics: Aging; Animals; Male; Memory; Metformin; Mice; Mice, Inbred ICR; Rats | 2019 |
Metformin attenuates the D‑galactose‑induced aging process via the UPR through the AMPK/ERK1/2 signaling pathways.
Topics: Aging; AMP-Activated Protein Kinases; Animals; Antioxidants; Apoptosis; Auditory Cortex; Disease Mod | 2020 |
Metformin mediates cardioprotection against aging-induced ischemic necroptosis.
Topics: Aging; Animals; Autophagy; GTPase-Activating Proteins; Humans; Hypoglycemic Agents; Imidazoles; Indo | 2020 |
Metformin Reduces Aging-Related Leaky Gut and Improves Cognitive Function by Beneficially Modulating Gut Microbiome/Goblet Cell/Mucin Axis.
Topics: Aging; Animals; Cognition; Diet, High-Fat; Disease Models, Animal; Dysbiosis; Gastrointestinal Micro | 2020 |
Dendrobium nobile Lindl alkaloid and metformin ameliorate cognitive dysfunction in senescence-accelerated mice via suppression of endoplasmic reticulum stress.
Topics: Aging; Alkaloids; Animals; Cognitive Dysfunction; Dendrobium; Dose-Response Relationship, Drug; Endo | 2020 |
CD4
Topics: Aged; Aging; Autophagy; CD4-Positive T-Lymphocytes; Cytokines; Humans; Inflammation; Metformin; Mito | 2020 |
Metformin Enhances Autophagy and Normalizes Mitochondrial Function to Alleviate Aging-Associated Inflammation.
Topics: Adult; Aging; Autophagy; Humans; Hypoglycemic Agents; Inflammation; Metformin; Middle Aged; Mitochon | 2020 |
Metformin regulates astrocyte reactivity in Parkinson's disease and normal aging.
Topics: Aging; Animals; Astrocytes; Corpus Striatum; Disease Models, Animal; Female; Male; Metformin; Mice, | 2020 |
Identification of longevity compounds with minimized probabilities of side effects.
Topics: Aging; Animals; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Glucosamine; Hu | 2020 |
Anti-Aging Effect of Metformin: A Molecular and Therapeutical Perspective.
Topics: Aging; Cellular Senescence; DEAD-box RNA Helicases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2020 |
Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status.
Topics: Aged; Aging; Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Cognition; Cognitive Dysfuncti | 2020 |
Next steps in mechanisms of inflammaging.
Topics: Aged; Aging; Autophagy; Humans; Inflammation; Metformin; Mitochondria; Reactive Oxygen Species | 2020 |
How anti-ageing drugs could boost COVID vaccines in older people.
Topics: Adult; Aged; Aging; Animals; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Va | 2020 |
Loss of metabolic plasticity underlies metformin toxicity in aged Caenorhabditis elegans.
Topics: Adenosine Triphosphate; Aging; Animals; Caenorhabditis elegans; Caloric Restriction; Glycolysis; Hum | 2020 |
Metformin treatment in late middle age improves cognitive function with alleviation of microglial activation and enhancement of autophagy in the hippocampus.
Topics: Aging; Animals; Autophagy; Cognition; Hippocampus; Male; Metformin; Mice; Mice, Inbred C57BL; Microg | 2021 |
Comment on Samara et al. Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study. Diabetes Care 2020;43:2691-2701.
Topics: Aged; Aging; Cognitive Dysfunction; Dementia; Diabetes Mellitus, Type 2; Humans; Metformin | 2021 |
Response to Comment on Samara et al. Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study. Diabetes Care 2020;43:2691-2701.
Topics: Aged; Aging; Cognitive Dysfunction; Dementia; Diabetes Mellitus, Type 2; Humans; Metformin | 2021 |
Tackling the pillars of ageing to fight COVID-19.
Topics: Aging; Cohort Studies; COVID-19; Humans; Metformin; Retrospective Studies | 2021 |
Long-term administration of metformin ameliorates age-dependent oxidative stress and cognitive function in rats.
Topics: Aging; Animals; Antioxidants; CA1 Region, Hippocampal; Cognitive Dysfunction; Male; Memory Disorders | 2021 |
Diabetes induces macrophage dysfunction through cytoplasmic dsDNA/AIM2 associated pyroptosis.
Topics: Aging; Animals; Antigen Presentation; Chemotaxis; Cytokines; Cytoplasm; Diabetes Mellitus, Experimen | 2021 |
Can Metformin Downshift the Gears of Aging to Slow Emphysema Progression?
Topics: Aging; Emphysema; Humans; Metformin; Pulmonary Emphysema | 2021 |
Metformin and leucine increase satellite cells and collagen remodeling during disuse and recovery in aged muscle.
Topics: Aging; AMP-Activated Protein Kinases; Animals; Body Weight; Collagen; Fibrosis; Hindlimb Suspension; | 2021 |
The Gut Microbiome, Metformin, and Aging.
Topics: Aging; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Humans; Hypoglycemic Agents; Metformi | 2022 |
Caloric Restriction Mimetics Slow Aging of Neuromuscular Synapses and Muscle Fibers.
Topics: Aging; Animals; Antioxidants; Caloric Restriction; Cells, Cultured; Disease Models, Animal; Energy M | 2017 |
The Ethics of Anti-aging Clinical Trials.
Topics: Aging; Biomedical Research; Ethics, Research; Health Behavior; Humans; Informed Consent; Longevity; | 2018 |
Synergistic Effect of Rapamycin and Metformin Against Age-Dependent Oxidative Stress in Rat Erythrocytes.
Topics: Acetylcholinesterase; Aging; Animals; Cell Membrane; Erythrocytes; Glutathione; Iron; Lipid Peroxida | 2017 |
Identification of tissue-specific transcriptional markers of caloric restriction in the mouse and their use to evaluate caloric restriction mimetics.
Topics: 2,4-Dinitrophenol; Adipose Tissue, White; Aging; Animals; Bezafibrate; Caloric Restriction; Carnitin | 2017 |
Metformin ameliorates gender-and age-dependent hemodynamic instability and myocardial injury in murine hemorrhagic shock.
Topics: Aging; AMP-Activated Protein Kinases; Animals; Biomarkers; Cardiotonic Agents; Enzyme Activators; Fe | 2017 |
Anti-aging pharmacology in cutaneous wound healing: effects of metformin, resveratrol, and rapamycin by local application.
Topics: Acetyl-CoA Carboxylase; Administration, Cutaneous; Aging; AMP-Activated Protein Kinases; Animals; Cy | 2017 |
Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin.
Topics: Adamantane; Aging; Animals; Biomarkers; Body Weight; Brain; Dementia; Dipeptides; Galactose; Glycate | 2017 |
New tricks from old dogs join the fight against ageing.
Topics: Aging; Animals; Autophagy; Biomedical Research; Caenorhabditis elegans; Cellular Senescence; Diet, H | 2017 |
Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults.
Topics: Aged; Aging; Cross-Over Studies; Female; Gene Expression; Humans; Hypoglycemic Agents; Male; Metform | 2018 |
Metformin ameliorates the age-related changes of d-galactose administration in ovariectomized mice.
Topics: Aging; Animals; Anti-Inflammatory Agents; Antioxidants; Brain; Brain-Derived Neurotrophic Factor; Fe | 2018 |
Metformin reduces glucose intolerance caused by rapamycin treatment in genetically heterogeneous female mice.
Topics: Aging; Animals; Female; Glucose; Glucose Intolerance; Humans; Hypoglycemic Agents; Immunosuppressive | 2018 |
Cellular stress and AMPK activation as a common mechanism of action linking the effects of metformin and diverse compounds that alleviate accelerated aging defects in Hutchinson-Gilford progeria syndrome.
Topics: Aging; Alternative Splicing; AMP-Activated Protein Kinases; Animals; Cell Nucleus; Cellular Senescen | 2018 |
Streptozotocin-induced β-cell damage, high fat diet, and metformin administration regulate Hes3 expression in the adult mouse brain.
Topics: Aging; Animals; Basic Helix-Loop-Helix Transcription Factors; Brain; Diet, High-Fat; Gene Expression | 2018 |
Anti-ageing pipeline starts to mature.
Topics: Aging; Cellular Senescence; Clinical Trials as Topic; Drug Discovery; Humans; Metformin; TOR Serine- | 2018 |
Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model.
Topics: Aging; Animals; Cell Line, Tumor; Disease Models, Animal; Fatty Liver; Genome-Wide Association Study | 2018 |
Drug Synergy Slows Aging and Improves Healthspan through IGF and SREBP Lipid Signaling.
Topics: Aging; Allantoin; Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Drosophila melan | 2018 |
Ellagic acid reveals promising anti-aging effects against d-galactose-induced aging on human neuroblastoma cell line, SH-SY5Y: A mechanistic study.
Topics: Aging; Anilides; beta-Galactosidase; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Ella | 2018 |
AMP Kinase Activation is Selectively Disrupted in the Ventral Midbrain of Mice Deficient in Parkin or PINK1 Expression.
Topics: Adenylate Kinase; Aging; Animals; Dopaminergic Neurons; Drug Evaluation, Preclinical; Energy Metabol | 2019 |
Metformin treatment improves the spatial memory of aged mice in an
Topics: Aging; Animals; Apolipoproteins E; Cognition; Genotype; Hypoglycemic Agents; Metformin; Mice; Mice, | 2019 |
Gastric Emptying in Patients With Well-Controlled Type 2 Diabetes Compared With Young and Older Control Subjects Without Diabetes.
Topics: Adolescent; Adult; Age Factors; Aged; Aging; Diabetes Mellitus, Type 2; Diet, Diabetic; Female; Gast | 2019 |
Stimulation of Hair Growth by Small Molecules that Activate Autophagy.
Topics: Aging; Allyl Compounds; Alopecia; AMP-Activated Protein Kinases; Animals; Autophagy; Butyrates; Cell | 2019 |
Ellagic acid dose and time-dependently abrogates d-galactose-induced animal model of aging: Investigating the role of PPAR-γ.
Topics: Aging; Anilides; Animals; Apoptosis; Brain; Ellagic Acid; Galactose; Glutathione Peroxidase; Liver; | 2019 |
Pro-neurocognitive and anti-sarcopenic benefits of one-year metformin therapy in ovariectomized aged mice.
Topics: Aging; Animals; Anxiety; Behavior, Animal; Brain; Cognition; Disease Models, Animal; Drug Administra | 2019 |
One-carbon metabolism: an aging-cancer crossroad for the gerosuppressant metformin.
Topics: Aging; AMP-Activated Protein Kinases; Animals; Anticarcinogenic Agents; Carbon; Cell Transformation, | 2012 |
Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism.
Topics: Adenylate Kinase; Aging; Animals; Biguanides; Caenorhabditis elegans; Caenorhabditis elegans Protein | 2013 |
Metformin, aging and cancer.
Topics: Aging; Animals; Antineoplastic Agents; Cellular Senescence; Hypoglycemic Agents; I-kappa B Kinase; M | 2013 |
Metformin and rapamycin are master-keys for understanding the relationship between cell senescent, aging and cancer.
Topics: Aging; Animals; Cellular Senescence; Gene Expression Regulation; Humans; Hypoglycemic Agents; Immuno | 2013 |
Multifaceted aging and rapamycin.
Topics: Aging; Animals; Gene Expression Regulation; Hypoglycemic Agents; Immunosuppressive Agents; Mammals; | 2013 |
Mechanism of metformin: inhibition of DNA damage and proliferative activity in Drosophila midgut stem cell.
Topics: Aging; Animals; Animals, Genetically Modified; Bromodeoxyuridine; Cell Proliferation; Cellular Senes | 2013 |
Aging-associated reductions in lipolytic and mitochondrial proteins in mouse adipose tissue are not rescued by metformin treatment.
Topics: Adenosine Monophosphate; Adipose Tissue; Aging; AMP-Activated Protein Kinases; Animals; Blotting, We | 2014 |
Medical research: treat ageing.
Topics: Age of Onset; Aging; Animals; Biomarkers; Biomedical Research; Caloric Restriction; Clinical Trials | 2014 |
[Hormonal deficiencies in the elderly: is there a role for replacement therapy?].
Topics: Adjuvants, Immunologic; Aged; Aging; Androgens; Dehydroepiandrosterone; Diabetes Mellitus, Type 2; F | 2014 |
Metformin has wider implications than diabetes.
Topics: Aging; Animals; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Longevity; Metformin | 2014 |
Sex differences in aging, life span and spontaneous tumorigenesis in 129/Sv mice neonatally exposed to metformin.
Topics: Aging; Animals; Animals, Newborn; Body Temperature; Body Weight; Cell Transformation, Neoplastic; Es | 2015 |
Hyperactive mTORC1 signaling is unaffected by metformin treatment in aged skeletal muscle.
Topics: Age Factors; Aging; AMP-Activated Protein Kinases; Animals; Exercise Test; Histocompatibility Antige | 2016 |
Anti-ageing pill pushed as bona fide drug.
Topics: Aging; Animals; Caloric Restriction; Clinical Trials as Topic; Cognition Disorders; Diabetes Mellitu | 2015 |
Can We Stop Aging?
Topics: Aged, 80 and over; Aging; Animals; Bone Morphogenetic Proteins; Chronic Disease; Everolimus; Growth | 2015 |
A Trial for the ages.
Topics: Aging; Humans; Hypoglycemic Agents; Liver; Metformin; Mitochondria; Neoplasms | 2015 |
Prolonged metformin treatment leads to reduced transcription of Nrf2 and neurotrophic factors without cognitive impairment in older C57BL/6J mice.
Topics: Adipose Tissue; Aging; AMP-Activated Protein Kinases; Animals; Blood Glucose; Brain; Brain-Derived N | 2016 |
Metformin-mediated increase in DICER1 regulates microRNA expression and cellular senescence.
Topics: Adult; Aging; Animals; Caloric Restriction; Cell Line; Cell Nucleus; Cellular Senescence; DEAD-box R | 2016 |
Combined metformin and resveratrol confers protection against UVC-induced DNA damage in A549 lung cancer cells via modulation of cell cycle checkpoints and DNA repair.
Topics: A549 Cells; Aging; Antineoplastic Agents, Phytogenic; CDC2 Protein Kinase; Cell Cycle Proteins; Cell | 2016 |
Metformin Alleviates Altered Erythrocyte Redox Status During Aging in Rats.
Topics: Aging; Animals; Antioxidants; Cholesterol; Erythrocyte Membrane; Erythrocytes; Glutathione; Glycatio | 2017 |
Strategies and Challenges in Clinical Trials Targeting Human Aging.
Topics: Acarbose; Aging; Animals; Anti-Bacterial Agents; Biomedical Research; Clinical Trials as Topic; Cong | 2016 |
Antiaging Effect of Metformin on Brain in Naturally Aged and Accelerated Senescence Model of Rat.
Topics: Acetylcholinesterase; Aging; Animals; Antioxidants; Autophagy; Biomarkers; Brain; Gene Expression Re | 2017 |
Living to 120.
Topics: Acarbose; Aging; AMP-Activated Protein Kinases; Animals; Diet; Humans; Life Expectancy; Mechanistic | 2016 |
Metformin: Restraining Nucleocytoplasmic Shuttling to Fight Cancer and Aging.
Topics: Active Transport, Cell Nucleus; Aging; Animals; Caenorhabditis elegans; Humans; Metformin; Neoplasms | 2016 |
An Ancient, Unified Mechanism for Metformin Growth Inhibition in C. elegans and Cancer.
Topics: Acyl-CoA Dehydrogenase; Aging; Animals; Body Size; Caenorhabditis elegans; Caenorhabditis elegans Pr | 2016 |
Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care-based cohort study, with economic assessment of patient outcomes.
Topics: Aged; Aging; Cohort Studies; Cost of Illness; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipe | 2017 |
Alleviation of senescence and epithelial-mesenchymal transition in aging kidney by short-term caloric restriction and caloric restriction mimetics via modulation of AMPK/mTOR signaling.
Topics: Adult; Aging; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blott | 2017 |
Differential effects of metformin on age related comorbidities in older men with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Aging; Cardiovascular Diseases; Cohort Studies; Comorbidity; Dementia; Depr | 2017 |
Cancer and aging: more puzzles, more promises?
Topics: Aging; Animals; Female; Humans; Hypoglycemic Agents; Longevity; Metformin; Mice; Neoplasms; Phosphat | 2008 |
Metformin slows down aging and extends life span of female SHR mice.
Topics: Aging; Animals; Body Temperature; Body Weight; Drinking Behavior; Estrous Cycle; Feeding Behavior; F | 2008 |
Regulation of visceral adipose tissue-derived serine protease inhibitor by nutritional status, metformin, gender and pituitary factors in rat white adipose tissue.
Topics: Aging; Animals; Female; Gene Expression Regulation; Intra-Abdominal Fat; Metformin; Nutritional Stat | 2009 |
The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.
Topics: Adult; Aging; Body Mass Index; Creatinine; Genotype; Humans; Hypoglycemic Agents; Immunohistochemist | 2009 |
AMP-activated protein kinase deficiency exacerbates aging-induced myocardial contractile dysfunction.
Topics: Aging; AMP-Activated Protein Kinases; Animals; Calcium Signaling; Cell Membrane; Electrocardiography | 2010 |
Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice.
Topics: Age Factors; Aging; Animals; Blood Glucose; Body Temperature; Body Weight; Cholesterol; Chromosome A | 2010 |
Metformin and sex: Why suppression of aging may be harmful to young male mice.
Topics: Age Factors; Aging; Animals; Female; Hypoglycemic Agents; Longevity; Male; Metformin; Mice; Mice, 12 | 2010 |
Gerosuppressant metformin: less is more.
Topics: Adenylate Kinase; Aging; Animals; Breast Neoplasms; Cellular Senescence; Disease Progression; Enzyme | 2011 |
Metformin treatment has no beneficial effect in a dose-response survival study in the SOD1(G93A) mouse model of ALS and is harmful in female mice.
Topics: Aging; Amino Acid Substitution; Amyotrophic Lateral Sclerosis; Animals; Body Weight; Cell Count; Dis | 2011 |
Insulin sensitizers may attenuate lean mass loss in older men with diabetes.
Topics: Absorptiometry, Photon; Adipose Tissue; Aged; Aged, 80 and over; Aging; Blood Glucose; Body Composit | 2011 |
An old drug for new ideas: metformin promotes adult neurogenesis and spatial memory formation.
Topics: Adenylate Kinase; Administration, Oral; Aging; Animals; CREB-Binding Protein; Disease Models, Animal | 2012 |
Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation.
Topics: Aging; Animals; Cell Differentiation; Cerebral Cortex; CREB-Binding Protein; Embryonic Stem Cells; E | 2012 |
Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon.
Topics: Aging; AMP-Activated Protein Kinase Kinases; Animals; Blood Glucose; Blotting, Western; Cardiotonic | 2013 |
Chronic activation of AMP-activated kinase as a strategy for slowing aging.
Topics: Aging; AMP-Activated Protein Kinases; Enzyme Activation; Humans; Insulin-Like Growth Factor I; Metfo | 2004 |
Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments.
Topics: Aging; Animals; Blood Glucose; Cell Membrane; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptid | 2004 |
Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
Topics: Adult; Aging; Androstenedione; Anti-Mullerian Hormone; Case-Control Studies; Estradiol; Female; Foll | 2005 |
Contraindications can damage your health--is metformin a case in point?
Topics: Acidosis, Lactic; Aging; Contraindications; Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hypog | 2005 |
Gerontology: eat your cake and have it.
Topics: Aging; Animals; Caloric Restriction; Cellular Senescence; Drug Evaluation, Preclinical; Drug Industr | 2006 |
Prenatal growth restraint followed by catch-up of weight: a hyperinsulinemic pathway to polycystic ovary syndrome.
Topics: Aging; Androgen Antagonists; Body Weight; Child; Drug Therapy, Combination; Female; Fetal Developmen | 2006 |
Predictors of metabolic control at one year in a population of pediatric patients with type 2 diabetes mellitus: a retrospective study.
Topics: Adolescent; Aging; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Education; Fami | 2006 |
Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy.
Topics: Acetylcysteine; Acute Kidney Injury; Adult; Aging; Child; Chronic Disease; Contrast Media; Drug Inte | 2007 |
Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy.
Topics: Acetylcysteine; Acute Kidney Injury; Adult; Aging; Child; Chronic Disease; Contrast Media; Drug Inte | 2007 |
Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy.
Topics: Acetylcysteine; Acute Kidney Injury; Adult; Aging; Child; Chronic Disease; Contrast Media; Drug Inte | 2007 |
Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy.
Topics: Acetylcysteine; Acute Kidney Injury; Adult; Aging; Child; Chronic Disease; Contrast Media; Drug Inte | 2007 |
Metformin decreases plasma insulin levels and systolic blood pressure in spontaneously hypertensive rats.
Topics: Aging; Animals; Blood Glucose; Body Weight; Hypertension; Insulin; Insulin Secretion; Male; Metformi | 1994 |
Metformin decreases blood pressure and obesity in OLETF rats via improvement of insulin resistance.
Topics: Aging; Animals; Blood Glucose; Blood Pressure; Blotting, Northern; Body Weight; Diabetes Mellitus, T | 1996 |
Increased alanine uptake and lipid synthesis from alanine in isolated hepatocytes of Wistar-Kyoto fatty rats: an inhibitory effect of biguanides.
Topics: Aging; Alanine; Animals; Body Weight; Buformin; Cells, Cultured; Diabetes Mellitus, Experimental; Di | 1997 |
Metformin does not alter diabetes incidence in the NOD mouse.
Topics: Aging; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Female; Glycosuria; Hypoglycemic Agents; I | 1997 |
Metformin and ageing diabetic patients.
Topics: Acidosis, Lactic; Aged; Aging; Diabetes Mellitus, Type 2; Health Services for the Aged; Humans; Hypo | 2000 |
Metformin, but not exercise training, increases insulin responsiveness in skeletal muscle of Sprague-Dawley rats.
Topics: Aging; Animals; Body Composition; Drinking; Eating; Glucose; Glucose Tolerance Test; Glycogen; Hypog | 2001 |
DBM mice as a pharmacological model of maturity onset diabetes. Studies with metformin.
Topics: Aging; Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Experimental; Disease Models, A | 1979 |